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Implementering av multidose i en kommunal 
hjemmetjeneste: Innvirkning på sikkerhet i 
legemiddelhåndteringen 
Multidose er tabletter og kapsler pakket maskinelt i poser for hvert doseringstidspunkt. I 
2005 besluttet Trondheim kommune å innføre multidose til brukere i hjemmetjenesten. 
På det tidspunktet var effektene av multidose mangelfullt dokumentert. 
Kommuneledelsen i samarbeid med NTNU, besluttet derfor å studere 
implementeringen. Multidose ble gradvis innført i 2006. 
Tre studier ble gjennomført for å undersøke kvaliteten og sikkerheten i 
legemiddelhåndteringen for pasienter i hjemmetjenesten før og etter innføringen av 
multidose. Samlet sett har studiene et komplekst design, med både interne og eksterne 
kontroller, og før - etter undersøkelser. Kvalitative så vel som kvantitative data ble 
samlet inn, og disse la grunnlag for metode-, kilde- og observatørtriangulering.  
Innføringen av multidose førte til bedre samsvar mellom medisinlistene hos fastlegene 
og hos hjemmetjenesten. Videre fant vi at medisinlistene hos fastlegene samsvarte bedre 
med medisinlistene på apotek enn hos hjemmetjeneste etter innføring av multidose. 
Imidlertid viste det seg at samsvaret for legemidler som administreres utenfor 
multidosesystemet (f.eks. øyedråper og inhalatorer) hadde en tilsvarende forbedring for 
den enkelte multidosebruker. Dette funnet tyder på at et økt fokus på 
legemiddelhåndteringen med informasjon- og opplæringstiltak samt nye rutiner som 
avklarer oppgaver og ansvarsforhold hos de ulike aktørene (fastlegekontor, apotek og 
hjemmetjeneste), var avgjørende. Funnene viser også at selv om antall 
uoverensstemmelser mellom medisinlister ble redusert, var forekomsten av avvik 
fortsatt høy. Dette forteller at flere tiltak og et kontinuerlig fokus på 
legemiddelhåndteringen er nødvendig for å etablere og opprettholde god kvalitet. 
Fastlegene så vel som farmasøytene rapporterte om bedre oversikt over pasientenes 
legemidler og dermed bedre kontroll. Involvert helsepersonell fortalte også om økende 
tillit til hverandre og til multidosesystemet etter hvert som nye rutiner ble implementert. 
Likevel ble tilliten til multidosesystemet utfordret av redusert fleksibilitet. Det 
opplevdes blant annet som vanskeligere å gjøre fortløpende endringer i medisineringen 
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sammenliknet med i det tidligere manuelle systemet som benyttet dosettesker. I tillegg 
uttrykte sykepleierne bekymring for at automatiseringen ville svekke deres kunnskap 
om den enkelte pasientens medisinering, og dermed gjøre dem mindre kompetente til å 
observere legemidlenes effekter og eventuelle bivirkninger hos pasienten. Fastlegene 
mente at elektronisk kommunikasjon kunne forenkle og forbedre utvekslingen av 
legemiddelinformasjon, og dermed bedre betingelsene for multidosesystemet. 
Fastlegene i Trondheim viste en positiv holdning til multidose. Det ble rapportert økt 
arbeidsmengde, men likevel ønsket de fleste fastlegene at multidosesystemet skulle 
videreføres. For å gjøre koordineringen i multidosesystemet mindre kompleks, besluttet 
Trondheim kommune at kun pasientens fastlege kunne forskrive legemidler til 
multidosepakkene. Den tydelige ansvarliggjøringen av fastlegene tvang dem til å ta et 
større ansvar for sine pasienters legemidler. Forbedrede rutiner og samhandling mellom 
fastleger, apotek og hjemmetjenesten omfattet imidlertid bare pasienter som var 
mottakere av multidose. Tilsvarende forbedringer skjedde ikke for pasienter som brukte 
vanlige dosettesker, selv om disse pasientene hadde samme fastlege og samme 
hjemmetjeneste som pasientene med multidose.  
I Trondheim førte innføringen av multidose til bedre kvalitet og sikkerhet i 
legemiddelhåndteringen for pasienter i hjemmetjenesten. Denne avhandlingen viser 
imidlertid at det viktigste bidraget til bedre kvalitet var vektleggingen av de ulike 
trinnene i legemiddelhåndteringen, bedre kommunikasjon og samarbeid mellom 
involvert helsepersonell, og avklaring av oppgaver og ansvar. Funnene kan ikke uten 
videre generaliseres, men innsikten som presenteres i denne avhandlingen kan være 
gyldig for andre som planlegger å innføre multidose eller som allerede bruker multidose 
i hjemmetjenesten. 
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Summary 
Multidose dispensed drugs are drugs machine-packed into dose unit bags for each time 
of administration. Trondheim municipality decided in 2005 to implement Multidose 
Drug Dispensing (MDD) in home care services. At that time, there was a lack of 
scientific knowledge about the effects of MDD. The health care management of 
Trondheim therefore decided to study the implementation in collaboration with NTNU. 
MDD was adopted gradually during 2006. 
Three studies were conducted with the common main aim of investigating the safety of 
medicines management during the implementation of MDD. A complex intervention 
was designed, including both internal and external controls, and pre-post-examinations. 
Qualitative as well as quantitative data was gathered, forming a method-, data source-, 
and observer-triangulation. 
The introduction of MDD reduced the discrepancies between the medication lists at the 
general practitioners (GPs), and in the home care services, and even moreso between the 
GPs and the pharmacies. However, for patients with multidose dispensed drugs, a 
corresponding improvement also occurred for drugs they received outside the MDD 
system (e.g. eye drops and inhalers). This finding suggests that new routines, and better 
collaboration between health practitioners, more than the MDD system by itself, 
contributed to the improvements. Nevertheless, even if the number of discrepancies 
between medication lists were reduced, the discrepancies continued to be high, 
demonstrating that more efforts are needed.  
Other reported improvements also occurred. Both the general practitioners and the 
pharmacists reported a better overview of the patients’ medication and thus a better 
control. The involved health care practitioners also stated an increased trust in each 
other, as well as in the MDD system, as better collaboration emerged. However, trust in 
the MDD system was challenged by a loss of flexibility to make changes in 
medication/dosage compared to the manual system. The nurses in the home care 
services expressed that the automation would decrease their knowledge of patients’ drug 
intake, and thus make them less trusted in observing patients. The GPs believed that 
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electronic communication could improve the exchange of information and updating, and 
thus produce an even better effect from the MDD system. 
The GPs in Trondheim showed a positive attitude to MDD. Increased workload was 
reported, but still most GPs wanted the system to be continued. The decision to only 
allow the patient’s GP to prescribe multidose dispensed drugs contributed to the 
improvements seen in routines of prescription, communication, and cooperation. The 
decision made the GPs take on a greater responsibility with their patients’ medications, 
and made the coordination in the MDD system less complex. However, the improved 
routines and collaboration between GPs and home care services and pharmacies, only 
related to patients receiving multidose dispensed drugs. The improvements were not 
transferred to other patients on the GP’s list having drugs administered by the home 
care services. 
The introduction of MDD in Trondheim was followed by improved quality in the 
medicines management. This thesis shows, however, that the main contribution to 
improved safety was emphasizing the different steps of the medicines management, to 
improvements in communication and cooperation between health care practitioners, and 
the clarifying of roles and responsibilities. The findings cannot be generalized straight 
forwardly. However, insights from the three studies presented in this thesis should be 
valid for others planning to implement an MDD system, or already using MDD in the 
home care services. 
  
X 
 
List of papers 
The thesis is based on the following papers: 
Paper I:  
Wekre LJ, Spigset O, Sletvold O, Sund JK and Grimsmo A, (2010): Multidose drug 
dispensing and discrepancies between medication records. Qual Saf Health Care 19(5): 
e42. 
Paper II:  
Wekre LJ, Melby L and Grimsmo A, (2011): Early experiences with the multidose drug 
dispensing system - A matter of trust? Scand J Prim Health Care 29: 45-50. 
Paper III:  
Wekre LJ, Bakken K, Garåsen H and Grimsmo A, (2012): GPs’ prescription routines 
and cooperation with other healthcare personnel before and after implementation of 
multidose drug dispensing. Scand J Public Health, 40(6): 523-530 
XI 
 
List of abbreviations 
ADE Adverse Drug Events 
EHR Electronic Health Record 
GP General Practitioner, doctor in primary care 
IMM Integrated Medicines Management 
MDD Multidose Drug Dispensing 
MMC Medicines Management Chain 
MRC Medical Research Council www.mrc.ac.uk/index.htm  
NOK Norwegian kroner 
NSEP Norwegian EHR Research Centre www.ntnu.no/nsep  
OP Ordinary Prescriptions 
  
XII 
 
 
1 
 
1. Background 
Multidose dispensed drugs are drugs machine-packed into dose unit bags for each time 
of administration (Sinnemaki et al. 2013). This thesis presents experiences with 
multidose drug dispensing (MDD), based on the implementation of such a system in the 
home care services in Trondheim. An important issue is the cooperation between 
different groups of health personnel involved in the medicines management chain 
(MMC). The patient’s GP, the nurses in the community home care services, and the 
pharmacists at the pharmacies, as well as the GP medical secretaries, are all central 
actors in the MMC. 
1.1 Medicines management chain 
A medicines management chain (MMC) is a collaborative chain. Collaboration in 
chains may be characterised as a sequential flow of tasks, where the actors work 
relatively independently (Paulsen et al. 2013). 
For patients living at home and in need of assistance in managing their medications, a 
complex and time consuming information sharing process takes place between numbers 
of different organizations: Home care services, GPs, pharmacies, and the MDD 
supplier. In addition, emergency units, nursing homes, rehabilitation services, and 
hospitals are often involved, as well as the patient and his or her friends and family. 
Each organization has to exchange and revise relevant information on their patients 
manually (Bakken et al. 2007).  
MMC may be divided into several processes or steps. A model used by the Joint 
Commission for Accreditation of Healthcare Organizations in the USA (later named  
The Joint Commission) considered five steps in MMC: prescribing, dispensing, 
administering, monitoring, and systems control (Nadzam 1991). Other models suggest 
four steps: ordering, transcription, dispensing, and administration (Leape et al. 1995) or, 
as based on observations of MDD in Trondheim: prescribing, ordering, dispensing, and 
administration (Hamre et al. 2010).  
As outlined above, an MMC includes a range of components; from human resources to 
technology. Firstly, the doctor concludes on medication; sometimes a straight forward 
2 
 
decision and in other cases, a decision based on the set of information seen in the 
medication of elderly patients with several chronic diseases (involving human 
resources). Thereafter, the doctor writes the prescription – mostly nowadays done 
electronically (involving both human resources and technology). The next steps usually 
involve the pharmacy supplying the patient or the institution with medicines (involving 
both human resources and technology). If the medicines delivered from the pharmacy 
are pre dispensed, an MDD supplier is involved (involving technology). In the end, the 
patient or a helper (e.g. home care services) administers the medicines (involving 
human resources, and sometimes technology). However, this is a diagrammatic view, 
and sometimes the process can be different. 
Each actor in an MMC is responsible for given tasks and for transferring the 
responsibility for the patients’ medications to the next actor. The next actor in the chain 
depends heavily on what the preceding actors have done. When work is organized into a 
sequential flow of tasks, the actors involved relate to each other asymmetrically 
(Paulsen et al. 2013). This in contrast to symmetrical collaboration, where actors meet 
in reciprocal encounters or face to face.  
New technology often creates additional work, as the individual actor does not gain the 
greatest benefit, but rather the next actor in the chain. Experience gained may encourage 
greater use (Grudin 1994). Thus, the new system should also seek to give all actors an 
advantage in one way or another to create a win-win situation (Grudin 1994). 
However, it has been claimed that the actor’s position in the chain is highly important 
for attitudes and motivation towards the collaboration, and that collaborative profit is 
greatest for the last actor in the chain (Barimani and Hylander 2008). To compensate for 
the missing motivation among actors, formalized procedures may be established (Nylen 
2007). 
Research shows that the quality of collaboration is affected by a number of factors in 
the organizational situation (Paulsen et al. 2013), and MDD may put in play several of 
these factors. Central factors discussed by others are organizational culture, conflicting 
professional attitudes, and lack of economic incentives (Anthony and Hudson-Barr 
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1998; Van Raak et al. 2005). Other important factors are timing, as well as distribution 
of tasks among actors involved (Paulsen et al. 2013). 
1.1.1 Obstacles hampering safety in the MMC  
Medication errors occur frequently in treatment with drugs and occur in all steps in the 
MMC (Runciman et al. 2003; Friedman et al. 2007). This may be due to poor 
communication about drug use or incomplete medication information (Glintborg et al. 
2007; Kripalani et al. 2007). Transferring patients between different levels of care is 
also associated with medication errors (Midlov et al. 2005). 
When looking at the different steps in the MMC, the preventable adverse drug events 
(ADE) among elderly in primary care most often occur during prescribing (58%), and 
monitoring (61%), but errors involving patient adherence (21%) are also fairly common 
(Gurwitz et al. 2003). 
Drugs are used frequently. Thus, the total number of preventable medication errors are 
costly (Cresswell et al. 2007). Hence, improving the MMC contains substantial 
potential for reducing the number of medication errors (Bates 1996). A study from the 
United States with elderly patients (65 years or older) receiving at least five 
prescriptions, estimated that the medication record reflected the reported medications 
accurately in only 5% of the patients (Kaboli et al. 2004). Norwegian studies have 
shown that there are discrepancies in the medication records in as many as 90% of 
patients receiving home care services (Jensen et al. 2003). On average, there are 25% 
more drugs listed in the medication records at the home care services than at the GP 
(Rognstad and Straand 2004).   
Repeat prescriptions account for over 80% of the total drug prescriptions, and a need for 
a repeat prescribing system to minimise the risk of ADE is emphasised (Zermansky 
1996; Avery et al. 2002).  
As already mentioned, transferring a patient between hospital and primary care is an 
event associated with medication errors. Medication errors may be due to poor 
communication about drug use when transferring patients from primary care to the 
hospital (Cornish et al. 2005; Midlov et al. 2005; Orrico 2008; Frydenberg and Brekke 
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2012), or at discharge from the hospital (Glintborg et al. 2007; Kripalani et al. 2007). A 
study from the United Kingdom considered readmission to hospital to be related to 
medication for 38% of the patients, and to be preventable for 61% of these 
(Witherington et al. 2008). Further, a Swedish study found errors in 25% of the drug 
orders to the MDD supplier at discharge from hospital (Alassaad et al. 2011).  
In addition, a Danish study found that only 14% of changes made in MDD drugs during 
hospitalization were communicated to the GP or to the community pharmacy. In the 
same study, discrepancies between medication lists from the hospital at discharge, and 
medication lists at home, were found in 50% of the patients (Reuther et al. 2011). These 
findings show that poor communication routines at discharge are also problematic in the 
MDD system. 
Within primary care, both the GPs and nurses in the home care services, depend on 
well-functioning collaboration - and communication routines. This is necessary to 
provide medical treatment for their shared patients. Thus, a synchronised and up-to-date 
overview of the medications of their patients is essential for both parties. Inaccurate 
medication records may cause medication errors and adverse drug events. 
Unfortunately, research has shown that even when changes in medication at other points 
in the MMC are communicated to the GP, not all GPs regularly update their medication 
records (Rognstad and Straand 2004; Bakken et al. 2007; Mandt et al. 2009; Rahmner et 
al. 2010).  
Further, when more than one physician is involved in the care of a patient, there are 
higher risks of medication errors (Bedell et al. 2000; Green et al. 2007). A Swedish 
study has also demonstrated a negative correlation between the quality of prescribing 
and the number of prescribers per patient in nursing homes using MDD (Olsson et al. 
2010).  
The preceding paragraph describes risks related to gaps. Gaps are discontinuities in 
care, and appear during interruptions in task solving, or when transferring information 
between actors. Mostly, health personnel are able to detect gaps, and act to avert failure 
(Cook et al. 2000). However, increased automation of work processes has been shown 
to make the processes less transparent to the collaborative actors, reducing the ability of 
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health personnel to prevent errors (Perry et al. 2005; Hamre et al. 2010). This has to do 
with a reduction in the many informal, preventive mechanisms (Ash et al. 2004); the 
pharmacists routinely check the doctors’ prescriptions, nurses check the drugs that were 
dispensed by the pharmacist, and so on. In manual processes, the chance of detection 
and prevention of errors is shown to increase with the number of actors involved in the 
process (Leape et al. 1995). Restructuring of the MMC may inadvertently eliminate 
some of these important and preventive mechanisms (Cook et al. 2000; Ash et al. 2004). 
1.1.2 Initiatives promoting safety in MMC 
Medication errors and ADEs have received considerable attention during the last 15-20 
years. In the report "To Err Is Human" (Kohn et al. 2000), it was indicated that the most 
frequent patient treatment inflicted injuries are drug-related. Prevention of drug related 
patient injuries was also one of six priority areas for a large U.S. patient safety 
campaign in 2004 (100 K campaign). The American Institute of Healthcare 
Improvement (IHI) has developed several recommendations for action within this area 
(www.ihi.org/imap). 
Internationally, several models have been developed to promote safety. The Integrated 
Medicines Management (IMM) model is based on a systematic approach to 
individualise and optimise drug treatment. The service is delivered across organisations 
and by a range of collaborating health personnel (Scullin et al. 2007). The IMM model 
covers all aspects of medicines management, starting with the prescription and ending 
with the patient’s use of the drugs. The overall goal is to achieve the best outcome for 
the patient at minimised costs (Scullin et al. 2007; Hellstrom et al. 2011; Ghatnekar et 
al. 2013). 
An IMM model from Northern Ireland was developed further in Sweden: the Lund 
Integrated Medicines Management (LIMM) model (Bergkvist et al. 2009; Hellstrom et 
al. 2011). In 2009, this model was introduced in Central Norway (Andersen et al. 
Accept. for publ.).  
A recent initiative is the Norwegian patient safety campaign, “In Safe Hands”. This 
campaign was launched in January 2011 by the Norwegian Ministry of Health. 
Prevention of drug-related patient injuries was one ‘in advance’, priority area in the 
6 
 
planned national patient safety campaign (Lauvrak and Norderhaug 2010). The three-
year campaign aims to reduce patient harm, and involves both specialist health care and 
primary health care. Medication reconciliation is an example of a focus area to improve 
the quality of medication lists in primary and secondary care. The campaign was 
focused on manual work processes to improve safety.  
1.1.3 Drug use among the elderly in MMC 
Elderly people make up the majority of drug users in the community. Numbers from the 
Norwegian prescription database shows that 91% of the elderly (65 years or older) 
received at least one prescription in 2011 (Rønning et al. 2012). Moreover, the elderly 
often use several drugs: 57% of the elderly use more than five drugs, while for the 
younger population, the proportion is less than 20% (Rønning et al. 2012). 
Although medications can alleviate symptoms and reduce elderly patients’ morbidity 
and mortality, drugs may also represent a potential danger through ADEs (Hanlon et al. 
1997). Problems in prescribing for the elderly arise from both the over-and under-
prescribing of medication therapies (Rochon et al. 1999). Several characteristics of 
ageing, such as decreased renal function and altered fat and water distribution, as well 
as potential mental impairment, make elderly patients particularly vulnerable to drug-
related harm (Rognstad et al. 2009; Ruths and Straand 2010). This means that great 
awareness is required when prescribing drugs or making dose adjustments for elderly 
patients (Wyller and Laake 2001).  
Polypharmacy is most commonly defined as concomitant use of five or more 
medications and is frequently seen in the older population (Viktil et al. 2007). In a 
Danish study among 212 elderly patients exposed to polypharmacy, the great majority 
of the patients (94%) had one or more inappropriate prescription (Bregnhoj et al. 2007).  
It is also shown that people with polypharmacy are associated with poor adherence 
(Wandless et al. 1979; Gryfe and Gryfe 1984; Griffith 1990; Barat et al. 2001). Further, 
it has been shown that persons living alone, and receiving more than three drugs from 
multiple prescribers, are at a higher risk of poor adherence (Barat et al. 2001). The 
relation between cognitive function and adherence shows, however, conflicting results 
(Barat et al. 2001). Interestingly, a recent study from the Netherlands reported that older 
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patients receiving multidose dispensed drugs had higher medication adherence 
compared to patients receiving manually dispensed drugs, despite a lower knowledge 
and lower cognitive function among the MDD users (Kwint et al. 2013). 
1.2 Multidose drug dispensing 
With MDD, patients receive their drugs machine-dispensed into dose units. The dose 
unit bags are labelled with patient data, drug content data, and time for intake (Bakken 
and Straand 2003; Bergman et al. 2007; Johnell and Fastbom 2008). All prescriptions 
are ordered through a local pharmacy, which electronically forwards the orders to an 
MDD supplier. Dispensed drugs are sent to the pharmacy, and the home care services 
deliver and sometimes administer the MDD drugs to the patients (Halvorsen et al. 
2011).  
 
Figure 1-1: Multidose dispensed drugs packed for two weeks use 
 
MDD has been promoted as a tool to ensure better medical treatment for patients with 
polypharmacy and/or with a limited ability to maintain appropriate medication use. 
MDD is assumed to be particularly suitable for patients enrolled in home care services, 
and long-term residents of institutions (e.g. nursing homes), due to the reduction of 
manual dispensing (Price Waterhouse Coopers 2007).  
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Further, MDD is expected to reduce medication errors, improve adherence, and reduce 
the waste of unused drugs (Riksförsäkringsverket 2001; Statens Helsetilsyn 2002; 
Kostiainen and Hyyppä 2004; Danish Medicines Agency 2006; Price Waterhouse 
Coopers 2007; Australian Government Department of Veterans' Affaires 2012). 
However, scientific evidence of these effects is missing (Nordling et al. 2009). In spite 
of the lack of scientific documentation, national authorities have voiced a strong 
confidence in the MDD system (Riksförsäkringsverket 2001; Helse- Og 
Omsorgsdepartementet 2005). 
In the home care services, the initiators for implementation of MDD are most 
commonly the municipal authorities or the municipal healthcare management. The main 
motivation is toward better quality, while improved effectiveness is also an important 
consideration.  
1.2.1 Multidose drug dispensing in Europe 
In Norway, MDD was first introduced to patients in the city of Drammen at the 
beginning of the 1990s (Apotekforeningen 2010). However, it was not before Farmaka, 
now one of the main MDD suppliers in Norway, started their production at the end of 
1999 that the marketing of the MDD system started. Still, it took considerable time to 
convince potential customers about the MDD product (pers. com. Cristina W. Haug). 
The number of MDD users in Norway in the years 2006-2012 is presented in Table 1-1. 
The table shows an extensive growth over the last seven years, with about 58,000 users 
in 2012 (Apotekforeningen 2013). However, it has been estimated at a potential 
inclusion of 70 000–120 000 patients from the primary care services until the year 2015 
(Apotekforeningen 2013). Of the current MDD users, about 80% are enrolled in the 
home care services (Apotekforeningen 2013). 
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Table 1-1: The number of users of multidose dispensed drugs in Norway during the years 
2006-2012 
 2006 2007 2008 2009 2010 2011 2012 
Number of multidose 
users in Norway 
16,000 22,000 31,000 35,000 44,000 53,000 58,000 
Growth from the 
previous year 
 39% 43% 14% 23% 21% 9% 
Sweden is the leading MDD country in Scandinavia, with about 182,000 users (Sjoberg 
et al. 2011), while Denmark had 63,000 users in 2012 (Statens Serum Institut 2013). 
Likewise, in The Netherlands the number of community dwelling MDD users increased 
strongly in recent years to 360,000 in 2011 (Kwint et al. 2013). MDD has also been 
introduced in Finland. It was implemented through legislation in 2011, and the number 
of MDD patients is currently about 20,000 (Sinnemaki et al. 2013). 
1.2.2 Multidose drug prescription forms 
Details about prescription form and content is provided in the public regulations 
concerning the requisitioning and dispensing of drugs from pharmacies (Helse- Og 
Omsorgsdepartementet 1998). The regulations say that multidose dispensed drugs might 
be prescribed through a medication list, where all the drugs of the patient, independent 
of drug classification (A, B or C), are listed. However, the prescription of class A-drugs 
(narcotics) must additionally be accompanied by a prescription form as required for this 
class of drugs. In the MDD list, the dosage and time for intake of the individual drug 
has to be specified. Just as with most other prescriptions, the medication list is valid as a 
prescription for one year. 
The multidose drug prescription form is not yet included in the Norwegian ePrescribing. 
1.2.3 Multidose drug dispensing and potential inappropriate drug 
use 
Swedish studies indicate that MDD users may be more exposed to potential 
inappropriate drug use (Bergman et al. 2007; Johnell and Fastbom 2008; Olsson et al. 
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2010). This is partly explained by higher drug use among multidose drug users than 
among patient receiving ordinary prescription (OP). It is suggested that the multidose 
drug prescription form may be regarded as complicated, hence resulting in uncritical 
renewal of prescriptions (Johnell and Fastbom 2008).  
This concern is supported by another Swedish study looking at the association between 
MDD and drug treatment changes in older hip fracture patients. The findings show that 
MDD is associated with fewer changes in drug treatment compared to OP (Sjoberg et al. 
2012). Likewise, a register based cross-sectional study showed that the greatest 
differences between MDD users and patients with OP were found to be related to 
quality indicators concerning the number of drugs; ten or more drugs, and three or more 
psychotropic (Sjoberg et al. 2011). 
However, Swedish MDD users seem to have a lower probability of potentially serious 
drug-drug interactions (Johnell and Fastbom 2008; Sjoberg et al. 2011). One 
explanation may be that drug-drug interactions warnings based on the complete 
medication list of the patients are given in the MDD prescribing procedure (Sjoberg et 
al. 2011).  
A Norwegian cross sectional study among MDD users in Norwegian nursing homes and 
home care services, found that more MDD users in nursing homes (31%) had 
potentially inappropriate drug use compared to MDD users in home care services 
(25%). Especially, increased co-prescribing of multiple psychotropic drugs was of great 
concern (Halvorsen et al. 2011). Still, the study suggests that MDD systems have 
potential for systematically identifying potentially inappropriate medications and drug-
drug interactions. Further, it was claimed that screening of patients’ medication records, 
and feedback to prescribers should be mandatory, to assure prescription quality in the 
MDD system (Halvorsen et al. 2011). 
1.2.4 Safer medicines management with multidose drug dispensing 
MDD may serve to enhance medication safety among primary healthcare patients 
(Sinnemaki et al. 2013). Still, even if automated dispensing systems are known to 
reduce dispensing errors (Klein et al. 1994), safety in the whole MMC may not be 
improved. An observation study conducted in three nursing homes using MDD in the 
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Netherlands, found a mean error frequency of 21% during the administration step of the 
MMC (Van Den Bemt et al. 2009). The most frequently occurring types of error were 
faulty administering techniques, especially incorrect crushing of medication. Further, 
safer management of medications demands that adequate procedures for drugs that 
cannot be included in the MDD system are also maintained (Heier et al. 2007; Van Den 
Bemt et al. 2009). 
A Danish study indicated that MDD did not improve compliance (Larsen and Haugbolle 
2007), while a study from the Netherlands claimed the opposite (Kwint et al. 2013). In 
addition, the multidose drug bags have been reported to be difficult to open 
(Søndergaard et al. 2005; Price Waterhouse Coopers 2007). Despite this, most 
medication users thought multidose dispensed drugs are an easier and safer solution 
than the traditional dose dispensers used in manual packaging (Figure 1-2) (Price 
Waterhouse Coopers 2007).  
 
Figure 1-2: A traditional dose dispenser on top of a medication record. The tweezers are 
used to grip the tablets when placing them into the correct partition of the dispenser 
According to official reports, the number of errors in dispensing are dramatically 
reduced with MDD (Riksförsäkringsverket 2001; Statens Helsetilsyn 2002). Yet when it 
comes to any effects on patient safety, health, and quality of life, scientific 
documentation is missing (Price Waterhouse Coopers 2007; Nordling et al. 2009). This 
means that any increase in safety as an effect of MDD is experience-based rather than 
evidence-based (Herborg et al. 2008). 
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One hypothesis has been that MDD can help reveal ambiguities between the prescriber, 
the pharmacy, the home care services, and the patient, thus helping to stimulate a more 
secure MMC. Norwegian studies have shown discrepancies between the medication 
record in the home care services and at the GP for patients receiving MDD (Bakken and 
Straand 2003; Heier et al. 2007). The earliest study (Bakken and Straand 2003) 
examined the rate of discrepancies that arose between what the doctor prescribed and 
the entries used by the home care services in three home care districts. The study 
showed that the rate of discrepancies were similar among MDD users (21%) and 
patients with OP (17% in one district and 33% in another district). One example of error 
in the district with MDD was that the doctor informed the home care services and not 
the pharmacy about changes made to the medication. 
In the second study (Heier et al. 2007), medication lists for 95 patients from three home 
care districts were collected from the GPs and home care services. These were 
compared for any disagreements. Discrepancies were found in 52% of the patients. 
Changes in medication were seen 20 times per month for every 100 users of MDD. On 
average, 19% of the patients in this study got manually dispensed medicines in addition 
to, or instead of, multidose dispensed drugs. 
The high rate of discrepancies was considered unacceptable in both studies. The 
common conclusion was that it is important to clarify who is responsible for the patients 
that are enrolled in home care services actually getting their prescribed medications. If a 
positive effect is achieved by the MDD system, it depends on the tasks and procedures 
introduced simultaneously. 
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1.3 Theoretical framework 
1.3.1 Complex interventions 
Complex interventions – consisting of multiple behavioural, technological, and 
organizational components – are common and important features of health care practice 
and research (May et al. 2007). Implementation of MDD in primary care falls within the 
definition of complex interventions. 
Complex interventions comprise a number of components, which may act both 
independently and interdependently, and it is often difficult to tease out the relationships 
between them (Medical Research Council 2000; May et al. 2007). Thus, research 
related to evaluation of complex interventions in big organizations is challenging, as 
problems may arise in developing, identifying, documenting, and reproducing the 
intervention (Campbell et al. 2000). But drawing on theories can help to conceptualize a 
problem and thus address it systematically (Campbell et al. 2007). The Medical 
Research Council’s (MRC) evaluation framework (Medical Research Council 2000) 
brought welcome clarity to the task. In 2008, the MRC updated its guidance (Craig et al. 
2008a). 
The MRC guide argues that almost all interventions, delivered by clinicians or research 
staff, are complex (Craig et al. 2008a). It is also claimed that complex interventions may 
work best if tailored to local circumstances rather than being completely standardised 
(Craig et al. 2008b). 
1.3.2 Work-arounds 
Health care professionals seek to balance technological and regulatory demands with 
the need to provide patient-centred care, in an efficient and cost-effective manner. They 
may simultaneously see a need to improvise or work around intended working routines 
to cope with time pressures and other obstacles. Such ‘work-arounds’ are frequently 
cited in the context of serious patient safety consequences (Halbesleben et al. 2008).  
It is shown that the introduction of quality and safety actions often cause changes in 
clinical processes. If the changes represent major practical obstacles, or are considered 
as unnecessary, or not meaningful, in order to complete the work, staff will redesign the 
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work processes to minimize the obstacles or to counter adverse effects. This does not 
happen suddenly, but often gradually over time (Ash et al. 2004; Halbesleben et al. 
2008).  
The web of human and technological interactions steadily going on in complex 
organisations typically involves humans solving problems with limited resources and 
working around imperfect processes (Coiera 2003). Knowledge about ‘work-arounds’ 
encountered during the implementation of new technology is shown to be of great 
importance (Vogelsmeier et al. 2008). To understand ‘work-arounds’, it is vital to know 
the workflow prior to, and during, the implementation.  
1.3.3 The Normalisation Process Theory  
Research on organizational development, technology implementation (especially ICT 
Information and Communication Systems) has developed a variety of theories anchored 
in sociology, computer science, economics, and management, etc. The Normalisation 
Process Theory (NPT) was developed by Carl May and his colleagues over the last 
decades as an attempt to adapt implementation theory to the health domain (May 2006). 
NPT theoretically assists in explaining the processes by which complex interventions 
become routines embedded in the daily health care practice (May et al. 2007). The 
model offers a framework for prospective process evaluation and also for comparative 
studies of complex interventions (May et al. 2007).  
The model focuses both on factors that promote, and factors that inhibit, the embedding 
of complex interventions into routines of health care practice (May 2006; May et al. 
2007; May et al. 2007; May et al. 2009; Murray et al. 2010). Further, in addition to 
studying endpoint outcomes, May and colleagues underline the necessity of evaluating 
social relations and work-related processes that lead to those outcomes. This they do in 
order to understand what produces the effectiveness of the intervention (May et al. 
2007). 
In particular, NPT guides attention to the processes by which complex interventions are 
made workable and integrated into everyday practice. Changes are produced by a range 
of social mechanisms described as sense-making work (coherence), engagement work 
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(cognitive participation), the work of enacting a practice (collective action), and the 
work of understanding and appraising its effects (reflexive monitoring) (May et al. 
2009).  
Normalisation is not the only possible outcome from an intervention. Other alternatives 
include: adoption, where a complex intervention is taken up, but does not become 
routinely embedded in everyday work, and rejection, where users refuse a complex 
intervention. De-normalisation may also occur during the lifetime of a complex 
intervention. Thus, normalisation is neither an automatic outcome, nor a permanent one 
(May et al. 2007). Some have claimed that the implementation requires on-going efforts 
to keep up the desired routines and effects of an intervention (Hanseth et al. 2006).  
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2. Aim and study questions 
The motivation for doing this research was the lack of documentation of effects of 
MDD, despite growth in the use of MDD in the period of planning the studies. The 
MDD system is mainly used in the home care services and offered to the elderly. The 
complexity both in the medicines management chain, and in the medication use among 
elderly, made the research area interesting and challenging from a pharmaceutical point 
of view. Also, from a health policy perspective, it was important to pay attention to the 
process of implementing MDD to point out success factors and possible challenges.  
The main aim of this thesis was to study possible changes in the safety of medicines 
management when implementing MDD in home care services. In relation to the model 
of Hamre et al, the main focus of this thesis has been on the step of prescribing, 
ordering and administering, and less on the step of dispensing. 
To achieve the aim, three studies were conducted. The overall aim was operationalized 
in four research questions: 
RQ-I: How does the introduction of MDD in a home care setting affect the number and 
nature of inconsistencies when comparing medication records from the GPs and the 
home care services?  
RQ-II: How do different groups of health professionals experience the change in the 
medicines management chain due to medication safety? 
RQ-III: How do the different actors in the medicines management chain alter their 
collaborative behaviour, roles, routines, and responsibilities when implementing MDD? 
RQ-IV: How do the GPs’ attitude towards the MDD system change during the 
introduction of the system?  
Table 2-1: The relation between research papers and research questions 
 Paper I Paper II Paper III 
RQ-I X X  
RQ-II  X X 
RQ-III  X X 
RQ-IV   X 
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3. Methods 
  2
  3
3.1 The MDD project 
The decision to implement MDD in the home care services in Trondheim was made by 
the municipal political authorities. The aim was improved quality in medicines 
management for the patient in the home care services. Thus, a two year MDD project 
was established to prepare, implement, and evaluate the introduction of MDD. 
The project was established in October 2005, and ended in September 2007. In total, 
there were 12 project meetings during this period. The project organization comprised 
the MDD project manager, the MDD Project Group, and MDD contact persons.  
The project group consisted of eight members representing the different actors in the 
MMC. Two persons represented the home care services, one person represented the 
GPs, one person represented the local pharmacy, and one person represented the MDD 
supplier. In addition, two project members came from the medical chief executive staff 
in Trondheim, and one of these was the project manager. The author of this thesis 
participated in the project group both as a project member (community pharmacist), and 
as a researcher (PhD-student). All members of the multidisciplinary project group were 
health personnel (nurses, physicians, pharmacists, and an ergonomist). There were no 
changes in the group throughout the two year project period. 
Most groups of actors in the MMC appointed an MDD contact person: Each of the 27 
different home care units appointed their own MDD contact person and so did the five 
pharmacies involved in MDD. Further, some GP practices appointed a GP medical 
secretary to be an MDD contact as well. 
For the MDD implementation project, an intranet website was established for 
publishing information about the project, minutes, written procedures, and so on.  
The four home care districts had different start-up times when introducing MDD for 
their patients: February, May, September and December, in 2006. 
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3.2 Setting 
3.2.1 Study place 
The study was conducted in Trondheim and Tromsø, Norway, in the years 2005-2007. 
At that time, around 3000 people in Trondheim received home care, including 1800 
receiving assistance in medicines management. Health care assistants and nurses 
represented around 500 man-years, and were organised into four geographical districts. 
The city of Trondheim had around 130 GPs during the study period, and five out of 17 
pharmacies were involved in MDD. The city of Tromsø served as a control in Paper III. 
Tromsø had 52 GPs at the time, and had not planned to implement MDD in the home 
care services. 
3.2.2 Information and training 
The members of the MDD project group were mainly involved in the information and 
teaching work. Additionally, the MDD contact persons at the different home care units, 
and in the pharmacies, had a responsibility for these tasks (information and teaching) 
within their own unit. In the pharmacies, the teaching was organized by the pharmacies 
together with the MDD supplier.  
The MDD contact persons at the different home care units, and at the pharmacies, 
received information directly from the MDD project group. They were responsible for 
communicating the information to their colleagues. In addition, mandatory information 
meetings about the MDD system, and the new routines, were held for all employees in 
the home care services who were involved in the medicines management before the 
implementation started.  
The home care services were responsible for providing the patients with information 
about MDD. Special information folders were composed and distributed to patients in 
the home care services (Anon 2005). This folder included the following headings: 
“What is multidose?”; “Who gets multidose?”; “What is improved?”; “How is 
multidose distributed?”; “What is the cost?”; “Who decides if you will receive 
multidose?”;  “Why implementing multidose?”  
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In addition, the MDD project group worked out written procedures for the handling of 
multidose dispensed drugs based on written procedures from the municipality of 
Stavanger. After approval by the medical chief executive of the municipality, the 
written procedures were made available on the intranet website of the MDD project.  
The GPs were informed about MDD in mandatory meetings, and written information 
was distributed. To make sure that all the information was made accessible, the 
procedures and information were gathered in a loose-leaf binder and distributed to the 
different GP practices. The MDD project manager paid a visit to the GP practices upon 
request. During implementation, a need was identified to provide the GP medical 
secretaries with information about MDD as well. Therefore, the GP practices were 
asked to appoint a contact person among their GP medical secretaries. This appointed 
GP medical secretary was responsible for following up the internal routines for 
prescription of multidose dispensed drugs. 
3.2.3 The local multidose drug dispensing system 
Figure 3-1 shows the formal MMC in the local MDD system. In Trondheim, the local 
procedure regulated the multidose packages to include only medications listed in the 
GPs medication record. Prescriptions made by other prescribers had to be evaluated by 
the patient’s GP in order to be handled within the MDD system. Thus, in Trondheim, 
only GPs had the exclusive right to prescribe in the MDD system. 
For patients receiving multidose drugs from the home care services, supply usually 
covers two weeks of use. If changes in the medications are made during this period, a 
repack may be ordered by the home care services. Alternatively, the home care services 
may choose to handle the changes manually by transferring the remaining multidose 
drugs into a pill dispenser, or giving an additional drug outside the multidose bags. 
However, changes may also be postponed until the next dispensing period. 
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Figure 3-1: The local medicines management chain within the multidose drug dispensing 
(MDD) system shown in a swim-lane diagram. Names of the different actors are written to 
the left in the diagram. When the actor had an electronic health record or another 
electronic system used in the MDD system, it is placed within the relevant actor’s box. The 
pharmacy and the MDD supplier is located in a common box since these actors chaired 
access to the multidose database, and information from the multidose database was also 
electronically loaded into the pharmacy system. The major steps in medicines 
management chain are shown as boxes. The order of the activities is moving from the left 
to the right. A “Drug list” is the complete medication record of the patient. The beige drug 
list was the one from the general practitioners and this was the prescription source in the 
multidose system. The yellow drug list was the medication list printed from the multidose 
database, while the orange drug list was the medication list registered at the home care 
services. A print of the drug list from the home care services was supposed to be handed 
over to the patient. In the model it is given a dashed frame as it was not always updated. 
‘‘EHR’’ is an abbreviation for electronic health record. “MDD” is an abbreviation for 
multidose drug dispensing. 
  
23 
 
3.3 Paper I 
The first paper explores the state of discrepancies in medication records at the GP’s 
office, and in the home care services before, and after, the implementation of MDD.  
3.3.1 Participants 
Ten home care units from two out of four home care districts in Trondheim recruited 
between 12 and 15 patients each for participation. The first 15 patients fulfilling the 
inclusions criteria were selected from the alphabetical patient list at each unit. In the 
end, 59 patients were included in the study.  
Inclusion criteria:  
x Written informed consent was obtained from the patient 
x The patient received assistance in medicines management by the home care 
services 
x The patient was given drugs from a dose dispenser (before the implementation 
of MDD) 
Exclusion criteria:  
x The patient lived in sheltered housing with care beds 
3.3.2 Design 
Paper I was a controlled pre-post study with pair design of patients’ medication records. 
In addition to a pre-post comparison of drugs administered in multidose packages, an 
internal control was obtained by comparing changes in the patient’s multidose 
administered drugs to the drugs administrated outside the MDD system. 
Medication records from the GPs and from the home care services were collected at two 
point of times: six months before, and one year after the start-up with MDD. In the post 
study, medication records from the pharmacies were provided as well.  
The MDD contact persons in the home care units recruited patients to the study. 
Further, the home care services were responsible for printing the medication records 
from their electronic health record (EHR) and collecting print-outs from the medication 
records at the GPs office for the pre-study. In the post-study, medication records for 
patients who were still users of the home care services, and still receiving MDD drugs, 
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were collected by the PhD student. This was done by sending a request for medication 
records directly to the patient’s home care unit, the patient’s GP, and to the pharmacy 
involved. 
3.3.3 Measures and data analyses 
The main measures in Paper I were pre- and post-measurement of discrepancies in the 
medication records at the GP office and at the home care services. The drugs were 
divided into three groups: 1) multidose drugs 2) non-multidose drugs (drug formulation 
not suitable for MDD) 3) drugs prescribed to be used as required.  
Discrepancies caused both by conflicting prescriptions, and by missing information in 
the medication records, were registered, in line with previous suggestions (Barat et al. 
2001; Bakken and Straand 2003; Jensen et al. 2003; Rognstad and Straand 2004; Arora 
et al. 2007). The sum of discrepancies in the pairs of medication records was registered 
and so was the sum of prescriptions in the medication record of the GPs (defined as the 
master record). The pairs of medication records with one or more discrepancy were 
counted as well. 
Discrepancies were rated into one of three classes according to whether they had 
minimal (Class 1), moderate (Class 2) or severe potential (Class 3) to harm patients. In 
addition, a fourth class of non-classifiable discrepancies (Class 0) was included. Similar 
classifications of discrepancies have been used by others who found the rating 
appropriate (Cornish et al. 2005; Arora et al. 2007).  
The rating of discrepancies was done by an expert group consisting of two pharmacists, 
a GP, a clinical pharmacologist, and a geriatrician. Each member of the group made an 
individual assessment before the joint evaluation. In cases of disagreement about the 
inconsistencies, the issue was resolved through discussion. Two meetings were arranged 
to disclose disagreements. Consensus was reached in all cases. The members of the 
group were blinded with regard to whether the records they inspected were collected 
before or after MDD was implemented. 
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Furthermore,  sum of risk scores in each pair of medication records were calculated by 
giving a Class 1 discrepancy 1 point, a Class 2 discrepancy 2 points, and a Class 3 
discrepancy 3 points. Class 0 discrepancies gained no points.  
Thus, to study the severity of the discrepancies, medication records at high-risk were 
defined by the following criteria: 
x Records where the sum of risk-scores were six or higher, or 
x Records containing one or more Class 3 discrepancies 
Analyses were completed using Microsoft Office Excel and SPSS. The statistical 
analyses used were the Student t-test for paired samples for continuous data and the 
McNemar test for paired nominal data.  
3.3.4 Sample size calculation 
Based on data from previous studies (Bakken and Straand 2003; Jensen et al. 2003; 
Rognstad and Straand 2004), we expected to find discrepancies in 80% of the 
medication records before intervention took place. In view of the numbers, we decided 
to consider discrepancies in 50% of the medication records in the post measure to be 
regarded as a positive effect of the intervention. Sample size was calculated by 
assuming that we wanted to detect this difference as statistically significant at 5% level, 
with a power of 80%, indicating that we needed to include 49 patients in the study 
(Pocock 1999). Since we expected some dropouts, and since analyses would be 
performed on other variables with more categories, we decided to invite 150 patients to 
participate in the study. 
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3.4 Paper II 
This paper presents early experiences with MDD among different groups of health 
personnel in the MMC, based on four focus group interviews.  
3.4.1 Participants 
The selection of informants for the four focus group interviews was done strategically to 
catch informants who had characteristics or qualifications that were important in 
relation to the topics posed (Halkier 2002; Thagaard 2003). Thus, professionals from 
home care services (nurses), pharmacies (pharmacists) and GP practices (both GPs and 
GP medical secretaries), who had experienced the MDD system from different 
positions, were invited. This was done in order to capture as many, and as nuanced, 
experiences of the introduction of MDD as possible. 
To the focus group of home care nurses, we invited one informant from the first eight 
home care units that had introduced MDD. Six nurses showed up and both MDD 
contacts and other nurses were represented.  
Five pharmacies in Trondheim were involved in the distribution of multidose dispensed 
drugs. The MDD contact  at each pharmacy was invited, and took part in the focus 
group interview. The MDD contacts were responsible for the distribution of multidose 
dispensed drugs, and they also provided the cooperation with the other professional 
groups within the MMC.  
GP medical secretaries were selected on a more incidental basis, as not all GP practices 
had appointed a secretary responsible for MDD. Totally, six GP medical secretaries 
participated. These informants belonged to different practises, and it was ensured that 
the recruited informants had some experience in MDD.  
For GPs, there was a convenient sample. Every second GP in Norway meets on a 
regular basis to  discuss, or examine, various professional topics (Treweek et al. 2005). 
Participation in small groups is a requirement for maintaining their specialty as general 
practitioners. One such group of seven GPs participated in the interview. The 
informants belonged to different practices and had varying experience with MDD. 
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3.4.2 Design 
The focus group interviews were conducted in March 2007. This was considered the 
early phase of the implementation. The home care nurses participating in the interview 
belonged to units who had started with MDD in February (3 informants) or in May (3 
informants) the year before the interview.  
Homogenous focus groups were made by putting together informants of the same 
professions. Homogeneity is recommended in order to capitalise on the shared 
experiences of a group (Tjora 2012). 
Interview guides were developed and used by the moderator during the interview. The 
interview guides covered three main topics: Implementation and organizational 
development; Cooperation and communication; Patient safety and time use. These 
topics were the same for all interviews, but questions were adjusted to fit each group 
according to different tasks in the MMC. The interview guides were semi-structured. 
3.4.3 Data analysis 
Firstly, the interviews were transcribed by a master student. Next, the data material was 
reviewed by extracting significant statements within the text. Each author of Paper II 
read the transcribed interviews and made individual notes based on the different topics. 
During the review, different views and experiences in the focus groups, and within a 
specific focus group, were highlighted. When different understandings of central quotes 
emerged, the group had a discussion to agree on a common understanding.  
Several significant issues were brought up during analysis of the data. “Trust” stood out 
as a theme with important concerns attached, that the authors agreed to analyse in depth. 
Trust is often referred to as a crucial factor, especially in collaboration (May 2006), but 
has seldom been thoroughly analysed in studies of implementation of complex 
interventions. 
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3.5 Paper III 
Paper III presents changes in prescription routines, as well as changes in the GPs 
communication- and cooperation routines in the MMC.  
3.5.1 Participants  
All GPs in Trondheim and Tromsø were invited to participate in the study. In 
Trondheim (intervention), the overall number of GPs was 123 in 2005 and 137 in 2008, 
while in Tromsø (control), the number of GPs was 52 both years. In total, 82 (67%) and 
91 (66%) filled in questionnaires in 2005 and 2008, respectively, in Trondheim. The 
corresponding numbers were 39 (75%) and 29 (56%) in Tromsø. 
3.5.2 Design 
The data was gathered through a controlled pre-post questionnaire study. Two 
comparisons were done. Firstly, GPs in Trondheim were compared to GPs in Tromsø 
(external control). Secondly, for GPs in Trondheim only, an internal control was 
undertaken by comparing changes in the MDD users’ drugs to changes in drugs given to 
other patients on the GPs’ lists in the home care setting. 
In the pre study (accomplished fall 2005), the same questions were answered by GPs in 
both cities, with the exception that the Trondheim questionnaire included additional 
questions about the MDD system. The post study was accomplished in January 2008. In 
the questionnaire in Trondheim, most questions were asked twice; firstly to get 
information about routines related to patients in home care services with ordinary 
prescriptions (OP) only, and secondly to get information about routines related to 
patients in home care services with MDD. In Tromsø, the questions were related to 
patients in home care services with OP only.  
GPs in Trondheim were given information about the MDD system, and the planned 
implementation, in mandatory meetings. The first questionnaire in Trondheim was 
answered by the GPs during this meeting. The second questionnaire was sent to the GPs 
together with an information letter. A reminder was given after three weeks. In Tromsø, 
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both questionnaires were handed out and collected at the GPs’ offices. One reminder 
was given after three weeks. 
3.5.3 Measures and data analyses 
The GPs in Trondheim and Tromsø were asked about prescription routines, 
communication, and cooperation with home care services and pharmacies regarding 
medicines management for patients receiving home care services. In addition, the GPs 
in Trondheim were asked about expected effects of MDD (in the pre-study), and 
experienced effects of MDD (in the post-study). 
The questionnaires had a multiple-choice design, including optional free-text comments. 
The completed questionnaires were scanned and data was transferred to SPSS. 
Statistical analyses were done with SPSS. A two sample t-test was used to compare 
mean values, while Fisher’s Exact test was used to compare the distribution of 
categorical variables. Logistic regression analysis was used to examine whether 
difference in odds of changing routines varied between intervention area and control 
area. Separate analyses were performed for responses that related to MDD users and 
patients with OP (Trondheim only).  
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4. Discussion of methods 
  4
4.1 The MDD project as a complex intervention 
The implementation of MDD fulfils the criteria of a complex intervention (May et al. 
2007). Therefore, steps outlined by the MRC guidelines (Medical Research Council 
2000; Craig et al. 2008a) were chosen as a base for the design and methods used in the 
MDD project. Even if the guidelines (Craig et al. 2008a; Craig et al. 2008b) recommend 
some degree of flexibility, tailoring, and adaption to a local setting, they were hard to 
follow all in all. 
Trondheim municipality is a large and complicated organisation that had to produce 
services as normal alongside the intervention. Trondheim wanted a scientific evaluation, 
but the needs of the patients, of the organisation, and the budget and time schedule, had 
priority. This put great restrictions on what the intervention could consist of, and limited 
the possibility of influencing the plan for the implementation. For this reason, the 
possibilities to undertake developmental work, or to measure allocations and risks, were 
also restricted.  
The complexity of the MMC of MDD is shown in Figure 3-1. The formal MMC in the 
local MDD system involved a number of actors from various organisations, and the 
interacting components included both human resources and technology. Thus, to make 
the intervention work, an exacting implementation process was required, focusing both 
on the actors, and on the processes within the MMC. Firstly, it was necessary to 
establish a common understanding of the context for the implementation. Furthermore, 
knowledge about the MDD system was needed to assess the feasibility of the 
intervention. 
4.1.1 Defining the context 
To succeed in developing and evaluating complex interventions, great attention has to 
be paid to the context in which the intervention takes place (Craig et al. 2008b; Murray 
et al. 2010). Thus it was important to ensure that the MDD project group had the full 
picture of the setting of the intervention. There were, for example, great differences 
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between the different units in the home care services regarding their organisation, 
human resources, and types of patient; subsequently, routines in the handling of drugs 
were different. Knowledge about variation in the handling of drugs between the 
different units was important to facilitate a standardised local adoption of the MDD 
system. At the same time, the procedures had to allow exceptions for single units, or 
single patients, where the MDD system was not expected to gain the patients.  
To be able to accommodate these considerations and make these decisions, a detailed 
knowledge about the characteristics of the intervention was needed as well; the patient’s 
capacities had to be assessed in relation to qualities of the MDD system. One example 
was small letters on the plastic bags indicating that MDD was not suitable for visually 
impaired patients. Another example were potential problems among patients with 
rheumatologic conditions in opening the plastic packages of drugs. To make room for 
exceptions within the MDD system, the formal procedures were locally tailored. 
However, the responsibility for deciding if the patient was suitable for MDD or not was 
standardised; the patient’s GP was responsible for making that assessment.  
4.1.2 Assessing feasibility 
Before implementing MDD in the home care services in Trondheim, the feasibility of 
introducing the new system had to be assessed. Even if some experiences were 
communicated in written reports from former local MDD implementation projects 
(Norli et al. 1997; Sjukehusapoteket I Skien 1999; Gombos and Norli 2000; Liavåg 
2002; Kartveit and Eide 2003; Norheim and Røed 2003; Wiik and Berg 2004), lack of 
sound former studies of MDD made it necessary to put much effort into planning. 
About 16,000 Norwegians already used multidose drugs when Trondheim introduced 
the system in 2006. Thus, the technology and the manufactured products were available 
in Norway. Further, the then current municipal procurement deal on drugs was offering 
delivery of multidose dispensed drugs to the home care services in Trondheim. This 
meant that the wanted product, multidose dispensed drugs, was available for 
Trondheim. 
The Norwegian health authorities requested the primary health care services to 
implement MDD (Andrew and Rygh 2000; Helse- Og Omsorgsdepartementet 2005). To 
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stimulate the implementation and use, the National Health Insurance Office started to 
refund NOK 500 per multidose drug user in home care services, per year, from 2003 
(Helse- Og Omsorgsdepartementet 2005). Still, no national guidelines were worked out 
for the implementation and use of MDD at the time, and every new implementation 
could be looked on as a new independent pilot. Altogether, the national 
recommendations and the economic contributions were interpreted as a promise of good 
feasibility.  
Still it could have been local circumstances making the intervention unfeasible: Were 
the different actors in the MMC motivated for the intended changes? Were resources 
(human resources and competence) available for planning, information and teaching, 
working out written procedures and so on?  
A study of discrepancies between medication records published prior to the MDD 
implementation, highlighted the safety issues related to medicines management in the 
home care services (Jensen et al. 2003). The study showed that the GPs had inadequate 
control concerning medicines management for patients in the home care services. The 
need for changes to improve this from a patient safety perpective were obvious.  
The heightened attention on this shameful situation seemed to motivate all actors in the 
MMC to take action toward improving the collaborative chain. Simultaneously, the 
MDD system demanded a greater degree of standardisation and rigidity than earlier. 
Research has shown this to be hard to accept for some of the individual health personnel 
(Greenhalgh 2008). Also, limited resources and local prioritization could be a challenge 
(Frankel et al. 2003). 
The greatest individualists within the different groups of health personnel in the MMC 
were the GPs. Even if most GPs work with other GPs, and share GP medical secretaries, 
the individual GPs have their own patients to follow up. Thus, the GPs are less 
dependent on cooperation and standardisation of their own tasks, and typically GPs 
show low organizational commitment (Kuusio et al. 2010). In Trondheim, however, 
there was one unit in the municipal administration dedicated to communicate with the 
GPs, and work on GP matters. The unit manager had a seat in the staff of the chief 
municipal executive. This made decisions taken within the MDD project group 
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authoritative. Since it has been shown that the first-line leaders play a key role in quality 
work in long-term care (Kjos et al. 2010), this might be a factor increasing the 
probability of success, thereby improving the feasibility of the project. 
Moreover, there was a possibility that the last actors in the collaborative chain, the 
home care nurses, could be less motivated for change, since they were dependent on all 
the other groups of actors. On the other hand, the consideration that the home care 
nurses could also be the most motivated for change found support in the literature, 
which said that often, the collaborative profits are greatest for the last actor in the chain 
(Barimani and Hylander 2008).  
Formalized procedures were established to secure standardisation of routines in the 
MDD system. In addition, the procedures may compensate for any missing motivation 
among the actors (Nylen 2007). Stavanger was among the cities already starting to use 
MDD, and their written procedures were used as a starting point for the local adoption 
in Trondheim. 
4.1.3 Choosing approach and design 
Deciding on evaluation methods was the next step. The MRC guidelines state that 
experimental designs are preferred to observational designs (Craig et al. 2008a). An 
individual, randomised trial at patient level was, however, not feasible. The MDD 
project represented an implementation of new procedures at an organisational level. In 
such situations, sometimes a cluster randomised design works well, but in this case, the 
three main collaborating partners, the home care services, the GPs, and the pharmacies 
represented different and crossing systems of clusters. In that case, there were two 
scientifically acceptable methods left that could serve the purpose; either interrupted 
time series or controlled pre-post studies (Wyatt and Wyatt 2003; Harris et al. 2006). 
Collecting copies of medication records several times in a row for this study would 
place a heavy burden on busy health personnel. The collection of copies probably had to 
be done manually by the actors in the chain, with the risk of a gradual loss of adherence 
to the study. Such a procedure would also go beyond the resources available for the 
study. For the purpose of Paper I, it was therefore decided to do a pre-post study with an 
internal control (Wyatt and Wyatt 2003). Using an internal control in Paper I not only 
35 
 
measured the pre-post difference for drugs included in MDD, but also the pre-post 
difference for drugs not suitable for MDD. Both groups of medications would be 
subject to the same non-specified factors that might or might not influence the 
intervention.  
The MRC guidelines also recommend a qualitative process study nested inside a 
complex intervention. It will often give a deeper insight into what happens, and a 
broader scope of the effects, including unintended effects. Thus, qualitative studies can 
be used to assess the quality of the implementation, eventually to clarify obstacles, and 
identify ‘work-arounds’ and possible influences of contextual factors (Lewin et al. 
2009). Also, a qualitative study, based on the participants’ experiences, can be used in a 
triangulation of the results of the intervention. However, it is most common the other 
way round, using quantitative research to test hypotheses brought up in qualitative 
research (Tjora 2012). The study published in Paper II was designed both to serve as a 
process evaluation, and for triangulation of results.  
A pre-post design with an external control was chosen for the study in Paper III. For 
several reasons Tromsø was picked as most eligible for becoming a control to 
Trondheim. Both were university cities, and relatively large by Norwegian standards. 
Both cities had a fairly similar organisation of the primary care services. The 
collaboration between the local health authorities and the GPs had been established over 
years in both places. Lastly, but most importantly, Tromsø had not planned to 
implement MDD in the time-frame of the study.  
In Paper III, separate analyses were performed for responses related to MDD users, and 
for patients with OP only (defined singularly for Trondheim). Thus, we obtained an 
internal control, enabling us to study whether possible changes in medicines 
management were achieved for both groups of patients (with MDD and without MDD) 
within the home care services.  
As outlined above, we had both external and internal control represented in the pre and 
post studies. The comparison of GPs in Trondheim to GPs in Tromsø constituted an 
external control in Paper III. Internal control was used both in Paper I and Paper III. In 
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Paper I, the internal control was related to individual patients, whereas the internal 
control was related to individual GPs in Paper III. 
4.1.4 The implementation process 
When evaluating complex interventions it is important to focus on the implementation 
process as well as the intervention effectiveness (outcomes); if an intervention is not 
implemented effectively, positive outcomes cannot be expected (Damschroder and 
Hagedorn 2011).   
According to the theoretical model of NPT, the intervention should be easy to describe, 
to provide coherence for the actors involved (Murray et al. 2010).The product, the 
multidose dispensed drugs, as well as the technology involved in the packaging and 
distribution of dispensed drugs, turned out to be quite easy to describe. The questions 
coming up during the implementation were mainly connected to how to solve practical 
tasks/problems. For example, how to handle changes in medications for MDD users.  
More challenging was the shift in distribution of tasks and responsibilities among health 
personnel in the preparation phase of the intervention. As recommended by the NPT 
(May 2006), policies were prepared to minimize disputes about division of labour. In 
addition to preparation of local procedures, the project exploited the support that could 
be found in the national policies regulating tasks and responsibilities within the MMC 
(Helse- Og Omsorgsdepartementet 1998; Helse- Og Omsorgsdepartementet 1999; 
Helse- Og Omsorgsdepartementet 2000; Helse- Og Omsorgsdepartementet 2008; Helse- 
Og Omsorgsdepartementet 2011).  
NPT further claims that the intervention should fit the overall goals and activity of the 
organisation, to improve collective action as well as coherence (Murray et al. 2010). 
The fact that the initiative to implement MDD came from the municipal management, 
acknowledged that the intervention was within the strategy of the organization of the 
home care services. Likewise, since the pharmacy management was quite pro-active in 
offering the MDD service, it indicated that there was a strategic commitment towards a 
large and important customer.  
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For the GPs, the strategic goal, seen from an organizational perspective, was more 
unclear and could become a factor inhibiting coherence and collective action in this 
group of actors. However, the organizational unit in the municipal administration, 
dedicated to communicate with the GPs, probably increased commitment to the project 
and stimulated collective action. In addition, the GPs were financially reimbursed for 
communicating patient information to the home care services and to the pharmacies. 
NPT says that incentives probably raised acceptance for the intervention (May 2006). 
Thus, the economic initiatives probably contributed to participation by GPs, despite the 
extra work load during the implementation of MDD. 
However, extra economic resources or personnel, e.g. for training or additional work, 
were not given to any other groups of health personnel. The different groups of actors 
had to produce services as normal, along with the intervention. According to NPT, this 
was a risk taken that could hamper the implementation (May et al. 2007), because even 
if most training was organized by the MDD project group, it could be a challenge to 
dedicate time for training. This was a possible inhibiting factor for normalisation.  
Since the responsibility for the implementation process was put on the MDD project 
group, modifications to the plan for implementation could be introduced during the 
project period if necessary, e.g. if unforeseen problems were reported.  
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4.2 Research in the MDD project 
4.2.1 Triangulation 
The logic behind triangulation is based on the premise that no single method ever 
adequately solves the problem of rival explanations. Because each method reveals 
different aspects of empirical reality, multiple methods of data collection and analysis 
provide more grist for the research mill (Patton 1999). To capture the many-faceted 
picture of a complex intervention, the guidelines, as well as literature in social science 
research methods, advocate use of multiple methods (Blackwood 2006; Campbell et al. 
2007; Craig et al. 2008b; Tjora 2012). Our research included both method-, data source-
, and observer-triangulation.  
Using different methods in the three studies (Paper I-III) highlighted agreement in 
results (Table V in Paper III). An example is the finding that GPs achieved increased 
cooperation with the pharmacy concerning the patients’ medications in the MDD 
system. This was found both in the qualitative study (Paper II) and in one of the 
quantitative studies (Paper III). When similar findings are seen in studies with different 
methodology, it strengthens the reliability and validity of the results. 
Data source triangulation was achieved by collecting data from different sources 
(Malterud 1996). In our case focus group, interviews involving different groups of 
health care practitioners (nurses, pharmacists, GP medical secretaries and GPs) were 
accomplished. Thereby information from actors who were positioned differently in 
relation to the problem in question (and in the MMC) was collected. An illustrating 
example is the discussion of cooperation between professional groups in the MMC; 
both the nurses and the GPs expressed an increased level of dialogue about medications 
administrated “as required” during the implementation of MDD.  
Observation triangulation was achieved as independent analysis of the transcribed 
interviews was accomplished by different researchers with various experiences 
(Malterud 1996). In the work with Paper II, three researchers with different experiences 
contributed; two of the authors had clinical experience in the field, and in addition two 
of the authors had experience from research on collaboration in health care. The 
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different experience and competence were valuable when discussing the meaning 
behind quotes in the material. 
4.2.2 Quantitative data 
Collection of data 
In a pre-post study, the collection of data should preferably take place under the same 
conditions before and after an intervention. For controlled studies, it is also important 
that the data collection is done similarly both in the intervention and in the control 
group. In our situation, we could not follow those recommendations strictly. Collection 
of data had to be adapted to the local circumstances and according to the resources in 
the project (Craig et al. 2008b).  
For the pre measurement in Paper I, the home care nurses collected the medication list 
from the GPs and handed them over to the study investigators together with printouts of 
medication lists from their own medication records. This gave the nurses an opportunity 
to scrutinise the lists before they were forwarded to the study investigators, but we have 
no signs indicating that this happened.  
In the post collection of medication records, the home care units and the GPs had, at 
least in theory, the chance to check their records against the medication lists they 
routinely received from the pharmacy when changes had been made in the MDD 
packages. Nevertheless, we consider this an unlikely scenario.  
In Paper III, the distribution and collection of data was done differently in Trondheim 
and in Tromsø (control). This could have biased the material, e.g. if the collection gave 
different opportunities for the GPs at the two sites to ask the researcher about 
clarification, or if members in one of the groups were in a bigger hurry when filling out 
the questionnaire. We cannot exclude the possibility that this occurred. All the same, the 
response rates were high, and similar, in both places. There are no indications that the 
method of distribution and collection affected the answers given by the GPs. 
Timing of data collection 
The timing for collection of data in Paper I and Paper III is illustrated in Figure 4-1.  
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Figure 4-1: Time for collection of data in the two pre-post studies (Paper I and Paper III)  
According to the early plan of Paper I, the measurements were planned to take place six 
months before and six months after the implementation. But because the 
implementation of MDD progressed more slowly than expected, the post-measurement 
had to be postponed to one year after implementation. This exemplifies adaptions of 
procedures to fit the local situation. The slow implementation might have resulted in 
differences in the material due to the length of multidose drug use for the individual 
patients. However, the start-up date for the individual patient was not registered in the 
study. Thus, we cannot tell whether the length of MDD use was a variable affecting the 
post-measurements. 
The delay in collection of medication records after the implementation might also have 
affected the finding of numbers of discrepancies. As time passed by, changes were 
typically made to the medications; hence, the possibility of discrepancies increased. 
However, the collaborative routines were expected to improve over time and lead to 
better agreement between the medication records. 
Furthermore, we decided to collect medication records for the post-measurements 
before the first annual review was performed by the pharmacies. At the time of the 
study, the written MDD routines stated that the pharmacies were supposed to demand 
an updated medication record from the patients’ GPs once a year. The intention was to 
obtain a new prescription (valid for one year), and to make a medication reconciliation 
of the list of medication at the pharmacies, which forms the basis for the drug 
dispensing.  
However, this routine was not established as intended. A new prescription was 
demanded only when renewal was needed due to durability. The planned medication 
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reconciliation would have revealed discrepancies between the medication list at the 
pharmacy/MDD supplier and the GP medication record, but not necessarily between the 
list at the pharmacy/MDD supplier and the medication record at the home care services. 
This latter aspect would depend on routines at the home care services during the 
changing of medication records when getting updates from the pharmacy. Therefore, it 
is difficult to tell if collection of medication records after the medication reconciliation 
would have given more, or less, disagreement in the post measurements. Yet since the 
routines changed, and the annual review was discontinued, the question becomes less 
relevant. 
In Paper III, there was quite a long time interval between the first questionnaire and the 
follow-up questionnaire. Thus, some effects following the introduction of MDD might 
have been weakened, cancelled out, or hidden by other changes made in the MMC. This 
could have been avoided by performing the after-study closer to the implementation, but 
then would be added the risk of the findings being influenced by start-up problems. The 
external control group was established to assess such effects (Brown et al. 2008).  
Moreover, making a series of measurements would have made the pre-post studies less 
dependent on good timing (Brown et al. 2008). As discussed above, this design was not 
possible to achieve within the resources of the project. 
Possible clustering effects 
Theoretically, it may be suggested that the design in Paper I could present problems 
because of a possible clustering of data. The patients were drawn from ten home care 
units, and within each unit, standardisation of internal routines may give clustering 
effects. However, most medication discrepancies and errors are related to the GPs’ 
routines in managing of prescriptions, and updating of the medication records. Only a 
minority have, in the literature, been related to the nurses’ routines (Gurwitz et al. 
2003). Medication records were collected from 39 GPs in 19 different GP practices 
where most had one or two patients that were enrolled into the study. We reasoned, 
therefore, that eventual clustering effects were small and negligible.  
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Validity of results 
The validity of a questionnaire study primarily depends on the measurements, and on 
good and well-formulated questions (Selltiz et al. 1976). Our questions were mainly 
taken from a questionnaire used by the local authorities in Trondheim (2005) less than a 
year before our research started. It was found feasible to use a questionnaire that had 
been tried before and that covered much of what we wanted.  
The manager of the data collection in Tromsø (who was a pharmacist and associate 
professor) provided input to the questionnaire. In addition, the two physicians in the 
project group helped reformulate the questions to improve the language, and to make it 
more unambiguous. One of these physicians was responsible for the questionnaire in 
2005, and reported a high level of validity of the questions in analysing the data. Since 
the person who originally made the questionnaire was involved in the revision, the first 
survey can be considered a pilot of the questionnaire.  
However, minor changes in lay-out, and wording, in the questionnaires may have 
resulted in different interpretations among the participants (Selltiz et al. 1976). We 
cannot rule out that this may have influenced the reliability, and validity, of the results, 
but evaluating the differences included in the questionnaires, we find this of minor 
significance. In retrospect, we still acknowledge that the questionnaire could have 
benefited from a more comprehensive validation before the first data collection. 
Next is the question of reliability, could we expect to get similar results doing 
comparable studies in other settings? In Paper I, we considered it convenient to select 
patients from an alphabetical list. As the selection was done by the patient’s last name, 
there could be an increased risk of drawing family members. This may have contributed 
to selection bias. Making the study use once more a random selection of participants, 
chosen via computer generated numbers, would have been preferred.  
In Paper I the dropout rate was 57%. The delay in the collection of medication records, 
after the implementation of MDD, probably increased the number of dropouts from 
deaths and people changing location. On the other hand, if the collection of medication 
records was done before the implementation was completed, dropouts would occur 
because all patients had not yet received multidose dispensed drugs. A potential 
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problem of a high dropout rate is that the sample size becomes too small to show 
statistically significant changes. Fortunately, this was not a problem in our case. 
In addition, the use of controls can be questioned. In Paper I, an internal control was 
applied. This method is supported by others when interventions are done at the 
organizational level (Wyatt and Wyatt 2003). An alternative approach would have been 
to include a control group of patients from the same municipality, who were not subject 
to MDD, but the implementation process in Trondheim precluded the possibility of this.  
The choice of Tromsø as a control city in Paper III seems adequate, since the two cities 
shared many of the same qualities. Both were large university cities in Norway, and the 
organization of the health care systems were comparable. Also, in Paper III an internal 
control was achieved at system level by asking the same question related to MDD users, 
and patients with OP who were in the home care services. 
Access to clinical data in Paper I could have made the classification of the discrepancies 
more reliable (Cornish et al. 2005; Nickerson et al. 2005). Yet, the classification used in 
this study has also been used by others (Arora et al. 2007) 
4.2.3 Qualitative data 
Composition of focus groups 
According to Morgan (1998), between six and 10 people normally participate in a focus 
group. We decided, however, to work with groups of relatively few informants. By 
doing this, we wanted to achieve a greater feeling of security, and gain opportunities to 
share personal stories and to express opinions (Morgan 1998). In this way, the 
participants were stimulated to become more engaged and emotionally involved with 
the topic. It also allowed the informants to relay their own experiences openly. Thus, in-
depth knowledge was achieved (Tjora 2012). 
Homogenous focus groups were composed. By forming focus groups based on 
professional groups, informants were “among equals”, and thereby a situation was 
avoided where, for example, GP medical secretaries withheld information because they 
were anxious to offend the GPs, who supposedly possessed a higher hierarchical status. 
The fact that the groups were homogenous also increased the confidence of the 
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participants when discussing various topics (Morgan 1998). Another positive effect of 
having professionally homogenous focus groups was that the informants considered 
each other to share some fundamental background. They did not need time to explain 
themselves to each other, but instead spent more time discussing the topics in question 
(Morgan 1998).  
There are also arguments in favour of bringing together a diverse group (for example, 
from a range of professions), to maximise the exploration of different perspectives 
within a group setting. In the latter case, it is important to be aware of how a hierarchy 
within the group may affect the data (Kitzinger 1995). In our case, the arguments for 
homogenous groups were stronger, and it also made the organisation of interviews 
simpler because some groups of actors were easier to meet in the evenings, while others 
preferred to meet during daytime. 
Interview guides 
It is important for the moderator to have an open mind and not be influenced by what 
the previous informants have expressed in other focus groups (Krueger 1998). This may 
be difficult, and one can expect various types of opinion based on what others have 
already said. However, people experience situations differently, and because of this, one 
hears statements that differ from each other, and are often contradictory. Respondents 
were not asked to comment on criticism raised by the others. 
To ensure the quality of the interview guides, people who had experience of focus group 
interviews, and a good knowledge of this field of study, were consulted. Two of the 
supervisors of this thesis assisted in the preparation of the interview guides. Advice on 
seeking help with the preparation of interview guides also came from Krueger (1998), 
who says that regardless of how experienced a researcher is, it is not appropriate for one 
person alone to design questions. To ensure the quality of questions, one requires 
feedback from others. Open and motivating questions were important to stimulate 
discussion, and capture the group dynamics (Krueger 1998).  
An explorative design, using a semi-structured interview guide, was chosen. The 
explorative approach was chosen to catch topics that the informants themselves might 
raise during the discussion. At the same time, structure was necessary to ensure that the 
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four different groups of informants discussed the same topics. Semi-structured focus 
group interviews are also the most common (Morgan 1998). 
The interview setting 
The focus group interviews were prepared and conducted in cooperation with a master’s 
degree student. The status of the interviewer was of great concern when the focus group 
interviews were conducted. The master’s degree student had previous experience in 
conducting focus group interviews, and just as importantly, she was not involved in the 
MDD implementation project. Therefore, she acted as a moderator in the focus group 
interviews. Since I was a member of the MDD project group, it was possible that this 
role could have influenced the informants (Wadel 1991). Thagaard (2003) writes that if 
the informants feel that the interviewer is authoritative or dominant, they may be 
inhibited from sharing experiences. In turn, significant opinions are missed. However, a 
moderator can never be completely neutral, no matter how hard he or she tries. Factors 
such as age, gender or race all play a part (Krueger 1998). 
My role in the interviews was to act as an observer, make notes, and capture the group 
dynamics. Sometimes I asked follow-up questions, and provided information on MDD 
when the informants had specific questions. It is possible that my role influenced the 
informants, but no indications were given that this actually did happen. 
The focus group interviews were carried out in the usability laboratory of the 
Norwegian EHR Research Centre (NSEP). We formed a triangle of tables, with the 
moderator at the top of the tables. The informants and the observer were seated around 
the tables. Cards with names were placed so that the participants could quickly find 
their own seat.  
To create a pleasant and friendly atmosphere, coffee, fruit, and biscuits were served 
during the focus group interviews. Conditions such as visibility, and sound in the room 
were also tested for adequacy. All these things are important to the execution of the 
focus group interview (Morgan 1998). 
In the usability laboratory at NSEP, there were cameras permanently positioned in the 
ceiling, and it was decided to use this equipment. Although the session was filmed, no 
reactions from the participants indicated that the technical equipment was bothersome. 
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The video recording, and the quality of the sound production from the recording 
equipment, facilitated the transcription of the focus group interviews.  
Transcription of the interviews gave a good overview, and knowledge about the 
material, before starting the analysis.  
Validity of results 
Within qualitative methods it is appropriate to embrace the concepts of credibility, 
conformability and transferability (Marshall and Rossman 2006). 
Credibility tells us if the research was carried out in a way that inspires confidence. E.g., 
if the informants had enough and relevant knowledge about MDD, and if the 
competence and experience within the group of researchers analysing the transcribed 
interviews were adequate. In Paper II, the selection of informants with adequate 
qualifications was safeguarded by inviting informants who had the preferred 
characteristics and experiences in MDD. The group of researchers possessed vital and 
complementary knowledge and experience in the field as well. 
An aspect discussed in Paper II is the timing of the interviews in relation to the 
implementation process. In an early phase of implementation, engagement and 
optimistic attitude may dominate, while later, actors might experience problems and 
adopt work-arounds. Furthermore, when complex interventions are integrated into 
everyday practice (normalised), it might be harder to reflect upon what consequences 
the intervention had in the organization and for the patients. In our case, the interviews 
were done in the early phase. Thus, the results presented in Paper II may be more 
optimistic than if they’d been gathered later in the implementation process. 
Conformability refers to objectivity; that is, the quality of interpretation, and if the 
understanding developed during this research is supported by other research (Polit and 
Back 2012). In our case, findings in the qualitative paper (Paper II) were in accordance 
with finding in the other two papers of this thesis. Furthermore, conformability is also 
dependent on the transferability that informs whether the interpretations based on a 
single study can be valid when transferred to other contexts (Polit and Back 2012). 
Already in Paper I, we argued that findings not only depend on MDD, but that the local 
procedures, and the implementation process, were of great importance to the outcome. 
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Similarly, in Paper II, there are reasons to believe that local circumstances did affect the 
findings. Therefore, generalisation of the findings must be expressed with caution.  
Common problems with interviews, and with discussions in focus groups, may be that 
questions are misinterpreted, that people cannot remember, or that they inadvertently 
“embellish” their answers. These common problems may jeopardize credibility and 
conformability (Polit and Back 2012). However, we experienced that the informants 
understood the questions, and since interviews were conducted only a short time after 
the introduction of MDD, the chances of forgetting were unlikely. As mentioned 
previously, it is possible that the informants were influenced by somebody already 
having a good understanding of the topic being present at the interviews. This could 
have resulted in individual informants “embellishing” their answers in a positive frame 
of reference. We cannot exclude the possibility that this happened.  
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4.3 Ethical aspects 
The studies were approved by the Regional Ethics Committee for Research in Medicine 
(REK), Central Norway and the Norwegian Social Science Data Services (NSD). The 
studies were conducted according to the Helsinki declaration (World Medical 
Association, 2004). All persons who were asked to participate were informed about the 
purpose of the studies and their right to withdrew without having to give any reason for 
their withdrawal. 
Patients recruited in the medical record study (Paper I) received written information 
about the study from a nurse in the home care services, and each patient in the study 
was asked to sign a letter of consent, allowing the collection of medication records from 
the GP, home care services, and the pharmacy. The members of the expert group 
evaluating the discrepancies were not able to see the patient’s name, as the pair of 
medication records was numbered, and the patients’ names were redacted on the 
distributed copies. The data used for statistical analysis was also depersonalized. 
Prior to the focus group interviews, we instructed the informants about the procedures 
for the interview. Video equipment was used to record both picture and sound from the 
focus group interviews. The groups were informed about the existence and purpose of 
the equipment before the interviews started. The audiotapes and transcripts were kept 
confidential, and all participants were de-identified in the transcription. 
For the questionnaire, the GPs in Tromsø received verbal information about the study as 
the questionnaires were distributed. In the initial round, the GPs in Trondheim also 
received verbal information, while in the second round an information letter was sent 
out along with the questionnaire. The GPs were all informed that the responses were 
anonymous. 
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5. Synopsis of the articles 
  5
5.1 Study 1 
Background: The objective of this study was to investigate whether implementation of 
multidose drug dispensing (MDD) for elderly outpatients is associated with a change in 
the number of discrepancies in the medication record at the general practitioners (GPs), 
and at the home care services.  
Methods: We carried out a controlled pre-post study, with paired design of patients’ 
medication records performed during implementation of MDD. Medication records 
from the home care units, and from the GPs, were reviewed, and the discrepancies were 
noted. The discrepancies were rated into four classes based upon their potential harm, 
and a risk score system was applied, giving the most potentially harmful discrepancies 
the highest score.  
Results: Medication records from 59 patients, with a mean age of 80 years, were 
included. The number of discrepancies was reduced from 203 to 133 (p<0.001), and the 
total risk score decreased from 308 to 181 after the implementation of MDD (p<0.001). 
For both the drugs subject to MDD, and drugs not suitable for MDD, the reduction in 
discrepancies was significant (39% and 31% reduction respectively).  
Conclusions: Calculated health risk due to discrepancies between the medication 
records from the home care services, and from the GPs, decreased during the time of 
implementation of the MDD system. It seems likely that most of the positive effect was 
caused by the change in routines, and enhanced focus on the medication process, rather 
than by MDD per se. 
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5.2 Study 2 
Objective: To study early experiences with multidose drug dispensing (MDD) among 
different groups of health personnel. 
Design: Qualitative study based on focus group interviews. 
Setting: Primary health care, Trondheim, Norway. 
Main outcome: The importance of trust in the technology, and in collaborating 
partners, is actualised in the early implementation of MDD. 
Results: GPs, home care nurses, pharmacists, and GP medical secretaries, trusted the 
new MDD technology. The quality of the GPs’ medication records improved. Still, 
health personnel, including the GPs themselves, would not always trust the medication 
records of the GPs. Checking the multidose bags arriving from the pharmacy was 
considered unnecessary in the written routines dealing with MDD. However, home care 
nurses experienced errors and continued to manually check the bags. Nurses in the 
home care services felt a loss of knowledge with respect to the patients’ medications. In 
turn, they experienced a reduced ability to give medical information to patients, and to 
observe the effects of the drugs. The home care services’ routines for medicines 
management were not always trusted by the other groups of health personnel involved.  
Conclusion: Health personnel faced some challenges during the implementation of the 
MDD system, but most of them remained confident in the new system. Building trust 
has to be a process that runs in parallel with the introduction of new technology, and the 
establishment of new routines for improving the quality in management of medicines, 
so to facilitate better cooperation and communication.  
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5.3 Study 3 
Background: This study addresses GPs’ attitudes towards multidose drug dispensing 
before, and after, implementation, and their perceived experience of how multidose drug 
dispensing affects prescription and communication routines for patients in the home 
care services. This study contributes to a method triangulation with two other studies on 
the introduction of multidose drug dispensing in Trondheim.  
Methods: A controlled pre-post study carried out in Trondheim (intervention) and 
Tromsø (control). A questionnaire was distributed to all GPs in the two towns in 2005, 
with a follow-up questionnaire in 2008.  
Results: The GPs in Trondheim showed a positive attitude to multidose drug dispensing 
both before, and after, the implementation. Increased workload was reported, but still 
the GPs wanted the system to be continued. Most of the GPs reported a better overview 
of the patients’ medication, and a supposed reduction in medication errors. The GPs’ 
prescription- and communication routines were changed only for the multidose drug 
users, and not for the other patients in the home care services.  
Conclusions: The study supports the results presented in two previous publications, 
related to GPs’ positive attitude towards multidose drug dispensing, their better 
overview of the patients’ medications, and improved cooperation with the pharmacy. 
This study adds to our understanding of prescription routines among GPs, and the use of 
the medication module in the electronic health record.  
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6. Discussion of findings 
  6
6.1 Perceived patient safety within the MDD system 
Improved quality in medicines management, and thereby increased medication safety, 
was a goal for all the actors involved in the introduction of MDD (Paper II). This 
engagement supported the implementation so that the MDD could be established as a 
regular practice (normalization) (Murray et al. 2010).  
An important issue related to medication safety, is whether the medications given to the 
patients are the same as those prescribed by the patients’ doctors. In the focus group 
interviews during the early phase of the implementation of MDD, informants had a 
common expectation that the intervention would reduce the number of discrepancies 
between medication records (Paper II). Their expectations were later confirmed when 
comparing medication records from the GPs, and from the home care services (Paper I). 
However, the same has not been demonstrated by other, similar, studies (Bakken and 
Straand 2003; Heier et al. 2007). Even if Paper I showed a reduction in discrepancies, it 
also demonstrated a great potential for further improvements to get more synchronized 
medication records.  
Improved agreement between the medication records could be the result of various 
factors. The establishment of common and well-known routines, before the start up with 
MDD, was suggested to be central to clarifying how, and to whom, different 
information should be addressed (Paper I-III). For the future, sharing of a common 
medication record is a solution already launched to avert discrepancies (Heimly 2008), 
but effects on medication safety are not revealed.  
Complexity may inhibit trust (Luhmann 1979), and trust is claimed to be the “glue” in 
interactive processes (May 2006). Both trust and power are generated at the inter-
personal level, and both play a critical role in shaping the quality of relations between 
organizations (Bachmann 2001). Thus, reduction of complexity improves the 
possibilities for the cooperative action that depends on trust (Luhmann 1979). The 
restriction imposed in Trondheim by only allowing the patients’ GPs to prescribe drugs 
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for inclusion in the multidose packages, was an example of how complexity in the 
MMC was reduced, and they thus eased the implementation process (Paper II and III).  
In addition, when implementing MDD, trust in the new technology was an important 
issue (Paper II). Technology-mediated trust is claimed to depend on the changing of 
human attitudes and behaviour (Rosenbloom 2000). The NPT also claims that the 
implementation of a complex intervention depends on collective action (Murray et al. 
2010). Thus, if the new technology creates a need for extra training, or big changes in 
work practices, the new technology may inhibit the implementation. Our findings, 
presented in Paper II, indicated that the health personnel involved trusted the technology 
used in MDD. Indeed, in order to safeguard information about the patients’ drug 
prescriptions, technology was necessary, and a lack of technology (e.g. ePrescribing) 
seemed to be a problem in the MMC, and became even more visible within the MDD 
system (Paper II). 
Moreover, findings presented in Paper II and III imply that implementing MDD was 
thought to be a good idea among the different healthcare professionals, and they found 
it worth investing time, energy and work. Thus, the cognitive participation among the 
actors was found to be satisfactory. According to NPT, this probably increased the 
possibilities of achieving normalisation (Murray et al. 2010).  
6.2 Obstacles within the MDD system 
Despite perceived safety within the MDD system, some obstacles and ‘work-arounds’ 
were reported (Paper II).  
When an intervention presents practical obstacles, or elements of the intervention are 
considered unnecessary, or not meaningful, in order to complete the work, actors will 
redesign the work process to minimize the obstacles (Ash et al. 2004; Halbesleben et al. 
2008). In the present intervention, the plastic bags with drugs were difficult to open for 
some patients, thus they needed extra help. Transferring the tablets from the plastic bags 
into e.g. egg cups before intake represents a risk, but also a way to overcome an 
obstacle. Such ‘work-arounds’ may lessen the reliability of the work processes, with the 
result being reduced patient safety (Halbesleben et al. 2008). 
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Further, it was reported that a loss of flexibility in prescriptions of drugs when 
implementing the MDD system, e.g. an interim change in dosage, was considered 
problematic in the MDD system (Paper II). For most patients, some drugs (like eye 
drops and inhalers, as well as drugs not taken regularly) had to be maintained manually 
in parallel with the multidose dispensed drugs, and for others only OP was suitable. 
This was an indication that the MDD system was not complete, and the old system (OP) 
had to be maintained together with the new system (MDD) to ensure the medications 
for all the patients in need of assistance from the home care services. Thus, additional 
use of OP was a way to work around an imperfect MDD system.  
In our study of medication records, 70% of all medications were found suitable for 
MDD (269 of 386 drugs before, and 298 of 424 drugs after the implementation of MDD 
- results not previously published). In contrast, a Swedish study reported that half of the 
drugs prescribed within the MDD system were delivered in whole packages 
(Wallerstedt et al. 2013). This may be caused by an insufficient flexibility of the 
Swedish system. However, the findings in our material and the Swedish study are not 
directly comparable; the numbers in our data of medication records came from 
categorisation of medication by formulation (e.g. tablets, eye drops, and inhalers) or 
dosage (regularly or when needed), while the numbers presented in the Swedish study 
were register-based (Swedish Prescribed Drug Register). 
The MMC within the MDD system is drawn in Figure 3-1. Although MDD systems 
have been called automation of the MMC, Figure 3-1 shows that there are still manual 
processes within the chain. The patient’s medication list is recorded several times 
during the process, and manual work still causes a risk of translation errors during the 
different steps of the process. In addition, there will always be a risk of adverse drug 
events because of errors in the communications between actors involved in the MDD, or 
when patients are transferred between various health care settings (Chhabra et al. 2012; 
Midlov et al. 2012). Therefore, automation in the updating of information between 
actors has been called for (Heimly 2008). On the other hand, it has been emphasized 
that automation processes in the handling of drugs may threaten the quality of many 
(hidden) manual work procedures (Hamre et al. 2010).  
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The system of electronic prescriptions has gradually been introduced in Norway. From 
the beginning of 2013, ePrescription was in use across the country. Even if MDD 
patients constitute more than 50,000 of the heaviest users of medicines in Norway, the 
functionality for multidose drug prescription is not yet in place in the ePrescription 
system. It will be included in a later version (pers. com. Ole Martin Winnem). In 
Sweden, a national electronic MDD database is well established. This MDD database 
has been located outside the physicians’ EHR, forcing the physicians responsible to 
document changes in dual systems. Thus, there is a risk of transcribing errors, or the 
omission of updated prescription information in one of the systems (Midlov et al. 2012).  
Focusing on the MMC drawn in Figure 3-1, the Swedish prescription model would 
remove the manual punching of data done at the pharmacy. Instead, punching must be 
done twice by the GPs. According to recent scientific results from Sweden, the solution 
for prescription within the MDD system should be integrated in the physician’s EHR 
(Sjoberg et al. 2011; Midlov et al. 2012; Sjoberg et al. 2012).  
As prescription turns electronic, the handover and access to the prescriptions will be 
simplified. However, the introduction of electronic systems are not unproblematic, and 
new problems or sources of error can occur (Bell et al. 2004; Koppel 2005; Grimsmo 
2006). To conclude, even if technology may contribute to improved patient safety, the 
systems are only as good as their users (Hidle 2007). Thus, technology can never fully 
replace human resources, and there will always be a need to improvise and develop 
‘work-arounds’.  
6.3 Cooperation among actors in the MMC 
All groups of health professionals in the MMC shared a concern about medication 
safety throughout the whole chain (Paper II). Their contributions may be seen as a 
collective action, which is one of four main components making an intervention become 
normalised according to the theoretical model of NPT (Murray et al. 2010).  
The actors especially were concerned about improved routines for the updating of 
medication records, to avoid inconsistency between themselves. We found that the 
intervention positively affected cooperation between the different groups of health 
personnel (Paper II and III), despite the fact that the actors experienced the changes to 
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be more challenging than expected beforehand (Paper III). MDD demanded more 
cooperation, as well as raising the general workload in the prescription phase compared 
to OP. 
6.4 Changes in roles, routines and responsibility 
Since the introduction of MDD resulted in changes to both tasks, and distribution of 
tasks, as well as responsibilities in the MMC, it could inhibit the embedding of the 
interventions into normalised routines of health care practice (May et al. 2007). 
Considerations about how the different groups of health personnel are affected by the 
intervention, if it promotes or impedes their work, and how compatible it is with 
existing work practices, are of the utmost importance to succeed with normalisation 
(Murray et al. 2010). 
In Paper II, we found that the nurses were uncomfortable with losing tasks, because 
they feared that their competency in medications, and knowledge about the individual 
patients’ drug use, would be reduced. Before the MDD system was implemented, the 
home care services had a hand in almost every stage in the MCC. They sent a request to 
the GP when renewal of prescriptions were needed, they ordered medication from the 
pharmacy, they delivered medication dosages in accordance with the medication list 
recorded in their own EHR, and in the end they assisted the patients by administering 
the drugs. When tasks were lost during the implementation of MDD, some of the hidden 
manual work also disappeared, and thus the sense of control was reduced (Paper II). 
When the nurses expressed a frustration over loss of control, it was evidence of a feeling 
of responsibility for the patient’s safety. One way of retaining control was to check the 
MDD packages when they arrived from the pharmacy. Findings in Paper II were 
recently supported by a Norwegian questionnaire study among nurses working in 
nursing homes. The nurses reported that MDD led to a loss of knowledge (79.5%), 
control (72.4%), and overview (72.4%) of the patients’ medications (Nilsen and Sagmo 
2012). 
For the other two groups of actors (the GPs and the pharmacists), changes in routines 
seemed to provide better system support for focusing on the complete medication list 
rather than just single prescriptions (Paper II and III). We found that the pharmacy 
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became an important communication partner within the MDD system (Paper II and III). 
This finding has also been reported by others (Berntsen and Hamre 2009).  
Further, improved prescription routines were reported by the GPs (Paper II and III). The 
change in prescription ratio made through the EHR medication module (Paper I), also 
indicated that the intervention affected the GPs’ prescriptions routines. However, the 
improved prescribing routines for the MDD patients were not transferred by the GPs to 
their other patients in the home care services (Paper III). For example, GPs consulted 
the EHR more often when prescribing to patients enrolled in the MDD system than 
other patients in the home care services. This implies that the introduction of MDD 
forced the GPs to assume greater responsibility for the medication of their patients 
(Paper II and III). Our findings support studies demonstrating a negative correlation 
between the quality of prescribing and the number of prescribers per patient (Bedell et 
al. 2000; Green et al. 2007; Olsson et al. 2010).  
Generally, formalisation of the changes was identified as an important success factor in 
the implementation of the MDD system (Paper II). This finding has been supported by 
others studying MDD (Heier et al. 2007; Kunnskapssenteret 2009).  
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7. Conclusion 
The present research was conducted to gain an insight into effects of the introduction of 
MDD in Trondheim, and how the different groups of health professionals welcomed the 
intervention. The implementation involved a number of actors from various 
organisations, and the interacting components included both human resources (mostly 
local), and technology (nationally available).  
The work has provided new knowledge about the MDD system applied in a home care 
setting. The results presented give an indication that the MDD system improved the 
quality in the management of medicines for the multidose drug users. However, changes 
did not seem to transfer to the patients in the home care services with OP. 
The process of implementation of MDD in Trondheim was associated with a reduction 
in discrepancies between medication records of the GPs and the home care services. 
Both the number of discrepancies, and the potential of the discrepancies to cause harm, 
were reduced. The reduction in discrepancies was significant both for dispensed drugs, 
and drugs not suitable for the automatic packaging system (drugs used only when 
needed, and drugs with unsuitable formulations, e.g. eye drops and inhalers).  
Improved quality in the MMC did not only appear by replacing traditional drug 
dispensers with multidose drug packages. The main contributions to improved safety 
were emphasizing the processes within the MMC, improvement of communication and 
cooperation between actors, and clarification of roles and responsibilities. Improving the 
procedures before implementing MDD is probably more important for proper medicines 
management, than the transition from manual to automatic dispensing. 
Changes in routines and roles required a higher level of trust between the groups of 
professionals. The different groups of actors involved in the MMC for patients in the 
home care services trusted the MDD system. However, trust was challenged by 
medication records being out-of-date, and by the loss of flexibility.  
The GPs showed a positive attitude to the MDD system, both before, and after the 
implementation of the system. Increased workloads were reported, but still the GPs 
wanted the system to be continued. Most GPs reported a better overview of their 
patients’ drugs, and a reduction in the number of medication errors. The GPs 
60 
 
prescription and communication routines were changed for the multidose drug users, 
but not for the other patients in the home care services. Restricting the right to prescribe 
multidose dispensed drugs to the GPs made the GPs take on a greater responsibility for 
their patients’ medications, and made the MMC within the MDD system less complex. 
Furthermore, common to all complex interventions is the importance of the setting in 
which the intervention is done. Because the setting will vary from place to place, the 
challenges of implementing MDD will vary as well. This means that the findings in 
evaluations of different interventions cannot be generalized straight forwardly. 
However, the insights from the studies presented in this thesis should though be valid 
for others planning to implement an MDD system, or already using MDD in the home 
care services.  
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8. Further research recommendations 
In this work, scant attention was paid to the patients – the multidose drug users. Nor is 
there much evidence published in the literature about how patients experience MDD. 
However, a Danish study, based on nine patient interviews, claims that the positive 
implications of switching to MDD, as assumed by health professionals and legislators 
before the implementations, did not occur among users (Larsen and Haugbolle 2007). 
Unfortunately, medication users are rarely a part of the health policy decision making 
process (Coulter 2004; Traulsen and Almarsdottir 2005), or involved in the 
development and assessment of new health technologies (Hansen 1992; Coulter 2004). 
This lack of user involvement also appears to apply to MDD (Larsen and Haugbolle 
2007). What consequences this may have are still unknown. 
It has been demonstrated that older patients know less about their medications and 
illnesses than younger patients (Granas and Bates 2005). Swedish studies on elderly 
patients show that the healthcare consumption pattern of those with less knowledge was 
different to those with more knowledge in terms of more acute inpatient care 
(Kristensson et al. 2010). Additionally, patients with polypharmacy had significantly 
less knowledge about their medicines than patients with fewer drugs (Modig et al. 
2009). It has also been claimed that adherence is related to the patients’ knowledge of, 
and attitude towards, medicines (Griffith 1990; Horne and Weinman 1999; Okuno et al. 
1999; Barat et al. 2001; Burge et al. 2005; Clifford et al. 2008; Menckeberg et al. 2008). 
When it comes to association between knowledge and adherence among MDD users, 
findings are contradictory; a study among 119 MDD users, and 96 patient with OP, 
performed in the Netherlands, shows that older patients using MDD had better 
medication adherence, but poorer medication knowledge, compared to patients with OP 
(Kwint et al. 2013). Yet a study from Sweden among 39 elderly patients did not show 
the same differences (Modig et al. 2009). Therefore, additional data on this concern is 
needed. 
The nursing role has previously been described as the last defence in a safety net to 
prevent errors (Leape et al. 1995). In Paper II, nurses reported that less attention was 
paid to medications after the introduction of MDD. Instead, the pharmacy was 
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highlighted as a new safety net. More research is necessary to examine the 
consequences of this potential change in responsibility both within and between the 
actors. 
To provide the pharmacist with more opportunity for control, better continuity in the 
follow-up of patients, and greater opportunities for professional intervention, are listed 
among the arguments for implementing MDD. In what ways do the pharmacy staff 
actually contribute to improving medication safety? Through detection of drug 
interactions, or better management of the patients’ medications in the MDD system? A 
randomised controlled study in the Netherlands reported that pharmacist-led medication 
review improved medication use among MDD users. Medication reviews by 
pharmacists are recommended, or provided, in Australia and Finland as well (Bell et al. 
2007; Australian Government Department of Veterans' Affaires 2012). However, 
evidence for this argument seems to be missing. 
The patients in the home care services are primarily elderly and sick people that 
circulate between health care-providers. Thus, when the patient receives multidose 
dispensed drugs, health personnel outside the primary care must also act in accordance 
with the MDD system. Studies looking at how health professionals in secondary care 
experience the MDD system are few and far between. However, a published paper 
concluded that when elderly patients are transferred from hospital to 
community/primary care, the main risk factor seems to be MDD, or rather the process of 
how to use it (Midlov et al. 2012). Interestingly, when the system was supported by 
clinical pharmacists, the error rate dropped to the same level as for patients with OP. 
More research is needed to learn how to best handle the MDD patient when moving 
between levels of care. 
When developing new technology, it is important to know about the existing 
technologies and processes. It is vital not to forget about hidden manual work, and the 
unspoken roles of health personnel in the former workflow. Thus, automation should be 
based on knowledge about which processes are important to maintain safe management 
of medication in the manual system. Workflow studies will make a good contribution to 
the results presented in this thesis, and will be helpful in providing a more differentiated 
description of the MDD system, and how it works in practice. Furthermore, workflow 
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studies might be helpful in providing insight into how to improve the existing MDD 
systems, and what one must be aware of when prescription of multidose drugs is 
included in the Norwegian ePrescribing.  
As prescription of multidose drugs turns electronic, knowledge about consequences of 
the new functionalities are demanded. E.g., the restriction made in Trondheim of 
allowing only the GPs to prescribe multidose drugs will cease. As discussed earlier, 
introduction of electronic systems are not unproblematic, and new problems and new 
sources of errors may occur (Bell et al. 2004; Koppel 2005; Grimsmo 2006). 
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NTNU            TRONDHEIM KOMMUNE
                                         
                   
SAMTYKKESKJEMA 
for deltagelse i studien ”Forebygging av utilsiktede hendelser med legemidler hos 
pasienter i hjemmetjenesten- Innføring av multidosepakkede legemidler og utvikling og 
utprøving av samtykkebasert elektronisk medisinkort i Trondheim” 
Jeg har mottatt informasjon om innføringen av nytt doseringssystem og ny løsning som gjør at 
hjemmetjenesten får tilgang til fastlegens medisininformasjon ved bruk av moderne datateknologi. Jeg 
er også informert om studien som skal vurdere nytten av nye rutiner og metoder for 
samhandling omkring medisineringen til brukere av hjemmetjenesten. 
Jeg gir herved mitt samtykke til å delta i studien, og at opplysninger i medisinliste fra 
hjemmetjenesten, fastlege og apotek blir benyttet til å vurdere kvaliteten av de nye tiltakene i 
kommunen. 
Trondheim,  
_________________________________
pasientens underskrift 
NB: Samtykket sendes kommuneoverlege Helge Garåsen. Kopi legges i pasientjournal hos hjemmesykepleien. 
            NTNU                                                                                                TRONDHEIM KOMMUNE
Til deg som mottar hjelp av hjemmetjenesten med dosering av medisiner
Informasjon og forespørsel om å delta i en studie som skal vurdere nytten av en ny måte å 
dosere medisinene dine på og for å få til en bedre samhandling mellom hjemmetjenesten og 
din fastlege 
Riktig medisin til riktig pasient er en meget viktig oppgave i den kommunale helsetjenesten. Oppgaven er 
tidkrevende for personalet og krever en stor grad av opplæring og oppfølging.  
Trondheim kommune jobber aktivt for å sikre at du som bruker av hjemmetjenesten skal få riktig medisin til 
riktig tid. To tiltak er nå satt i gang for å gjøre dette enda bedre:  
1) Innføring av ferdigpakkete doser av medisiner fra apoteket 
Den tradisjonelle ukedosetten skal erstattes med dosepakker (multidoser) fra apoteket. Undersøkelser 
viser at dette reduserer mulighetene for feil vesentlig. 
2) Utvikling og utprøving av elektroniske medisinkort 
Kommunen vil prøve ut en ny løsning som gjør at hjemmetjenesten får tilgang til fastlegens 
medisininformasjon ved bruk av moderne datateknologi. Dette vil sikre at hjemmesykepleien og din 
fastlege alltid har de samme opplysningene om dine medisiner.  
Vi ønsker å finne ut om disse tiltakene gir en sikre legemiddelhåndteringen for deg og andre brukere av 
hjemmetjenesten. Vi vil gjerne se på om medisinopplyningene hos fastlegen, i hjemmetjenesten og på 
apotek samsvarer bedre etter at vi tar i bruk våre nye rutiner.  
Vi ber derfor om at du samtykker i at vi i evalueringen av prosjektene får tilgang til opplysninger omkring 
dine medisiner hos hjemmetjenesten, hos fastlegen og på apoteket slik at vi kan sammenligne om alle har 
den samme og korrekte informasjonen om dine medisiner. All informasjon om dine medisiner vil bli brukt 
slik at det ikke vil bli mulig å spore noen opplysninger tilbake til deg som person. Når undersøkelsen er 
ferdig i år 2012, vil vi tilintetgjøre alle personidentifiserbare opplysninger som vi har samlet inn. 
Prosjektmedarbeidere har taushetsplikt i hht. Forvaltningsloven § 13 og Helsepersonelloven § 21. Alle 
persondata behandles konfidensielt og lagres i en database slik at pasientene er registrert med et 
løpenummer. Undersøkelsesresultat samt navneliste, hvor slike eksisterer, oppbevares forskriftsmessig. 
Deltagelse i studien er frivillig, og du kan når som helst trekke deg fra deltagelse i studien uten at du 
behøver å angi noen grunn. Dette vil ikke medføre noen konsekvenser for deg som bruker av 
hjemmetjenesten.
Vi håper at du synes dette er en nyttig undersøkelse og sier ja til at vi kan innhente informasjon om dine 
medisiner hos din fastlege, hos hjemmesykepleien og på apoteket. 
Prosjektet er vurdert og godkjent av Regional komité for medisinsk forskningsetikk, Midt Norge og er 
tilrådd av Personvernombudet for forskning, Norsk samfunnsvitenskaplige datatjeneste. 
Du kan stille flere spørsmål til personalet i hjemmetjenesten eller til kommuneoverlege Helge Garåsen på 
telefon 91112656. 
Trondheim, 10.03.2006 
Liv Johanne Sætern 
Farmasøyt/stipendiat       
NTNU
Helge Garåsen 
Kommuneoverlege 
Trondheim kommune
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SAMTALEGUIDE APOTEK 12.mars 2007 
Introduksjon ved Marte
- Hva er et fokusgruppeintervju
- Om gjennomføringen 
Implementering og organisasjonsutvikling 
Først i samtalen med dere vil vi få rede på hva dere synes om multidose og hvordan 
ekspedering av multidose har innvirket på deres arbeidssituasjon. 
1. Hva er deres erfaring med oppstarten av multidose? (godt/ikke godt) Er det ulike 
erfaringer fra de ulike apotek? 
a) Hva synes dere om informasjonen og opplæringen dere fikk i forkant? Hva 
besto dette i? Har alle ansatte fått opplæring i håndtering av multidose? 
b) To apotek, Heimdal og Saupstad, startet opp med multidose før de andre. 
Hvordan fungerte erfaringsoverføringen fra et apotek til det andre? 
c) Hvor godt kjent er du med de skriftlige prosedyrene til Trondheim 
kommune som omhandler multidose?  
d) Hvilke andre skriftlige prosedyrer har dere på apoteket som omhandler 
multidose (egne, fra Farmaka ea.). (Følges disse?) 
2. Multidose var nytt for apoteket og sikkert for de fleste ansatte. Dere fikk en 
mengde nye kunder og oppgaver i løpet av en relativt kort periode. Hvilken 
innvirkning har dette på arbeidefordelingen på apoteket? 
a) Multidoseansvarlig sin rolle? (Er dette en rolle som vil bli opprettholdt 
eller er det naturlig at den forsvinner når multidose er ”oppe og går”?) 
b) Da andre farmasøytene sin rolle? 
c) Teknikerne sin rolle? 
d) Apotekeren sin rolle? 
e) Hva med ledelsen i Alliance apotekene lokalt? 
Samarbeid og kommunikasjon 
Kommunikasjon og samarbeid har mye å si for hvor suksessfull 
informasjonsoverføringen er. Nå skal vi gå inn på tema om bruk av Farmapro og 
Farmaka sin programvare for overføring av informasjon. Vi vil også høre om 
samarbeidet mellom de ulike partene (hjemmesykepleie, apotek og fastlegene) som 
berøres av multidose. 
3. Vi starter med å diskutere samarbeid og kommunikasjon omkring multidose. 
a) Hvordan er informasjonsflyten internt på apoteket? 
b) Hvordan er informasjonsflyten apotekene imellom? 
c) Hvordan er informasjonsflyten mellom dere og hjemmesykepleien? 
Oppleves store forskjeller mellom sonene? 
d) Hvordan er informasjonsflyten mellom dere og fastlegene? Også her er vi 
interesserte i å høre om dere opplever store forskjeller mellom 
leger/legekontor og hvordan det evt håndteres? 
e) Hvordan er informasjonsflyten mellom dere og Farmaka? 
f) Får du all informasjon du trenger? 
g) Får du gitt all nødvendig informasjon? 
h) Hva med kommunikasjonen kan forbedres? 
Sikkerhet og tidsbruk 
Nå, som siste tema skal vi snakke om sikkerheten rundt multidose. Multidose ble 
innført for å bedre kvalitet i legemiddelhåndteringen og for å frigjøre sykepleiertid til 
andre oppgaver.
4. Først her skal vi ta utgangspunkt i bedring av kvalitet i legemiddelhåndteringen. 
a) Hvordan føler dere at dere som farmasøyter bidrar til økt sikkerhet og 
kvalitet? Er bidraget blitt endret etter at multidose ble innført? 
Hvorfor/hvorfor ikke? 
b) Hvilke feil har tidligere vært mest vanlig i forbindelse med ekspedering av 
legemidler til hjemmetjenesten?  
i. Har sjansen for å gjøre noen av disse feilene blitt redusert/forsvunnet? 
ii. Har dere oppdaget nye muligheter for feil som kommer av 
multidosesystemet. Har dere eksempler på dette? 
c) Har dere fått reaksjoner fra pasientene eller pårørende på multidose? (betaling, 
fleksibilitet, service?) 
d) Hvordan er overensstemmelsen mellom ordinasjonskortet på apoteket og 
medisinlistene til fastlegene? 
e) Noen pasienter skal ha noe medisin som ikke multidosesystemet tar seg av 
(eventuellmedisin og faste legemidler som ikke kan pakkes i multidose). 
Hvordan fungerer utleveringen av disse legemidlene? 
5. Hvordan foregår oppdateringen av ordinasjonskortet? 
i. Hvem gjør denne oppgaven? 
ii. Når blir denne oppgaven gjort? (kun når resept foreligger fra 
lege eller også når endringer blir meldt fra andre forskrivere 
eller fra hjemmetjenesten?) 
iii. Blir endringer som skrives inn i ordinasjonskortet kontrollert av 
en annen farmasøyt eller tekniker? 
iv. Føler dere dere trygge på at ordinasjonskortet til enhver tid er 
oppdatert? 
6. Nå skal vi diskutere hvordan multidose innvirker på deres tidsbruk.
a) I hvilken grad er ressursene på apoteket justert i forhold til påført 
arbeidsmengde med multidose? Har de nye oppgavene gitt:  
i. Endret bemanning? 
ii. Endret tid til andre oppgaver? I så fall hvilke?  
iii. Overtid? 
b) Har leveranse av multidose ført til at hjemmetjenesten etterspør andre 
tjenester? 
i. Gjennomgang av medisineringen til enkeltpasienter 
ii. Vurderinger av effekter, bivirkninger, kontraindikasjoner og 
interaksjoner 
iii. Pasientinformasjon/opplæring 
iv. Andre farmasøytiske tjenester? (undervisning, skriftlig 
informasjon, synonymliste…) 
c) Har leveranse av multidose ført til at fastlegene etterspør andre tjenester 
enn tidligere? 
i. Gjennomgang av medisineringen til enkeltpasienter 
ii. Vurderinger av effekter, bivirkninger, kontraindikasjoner og 
interaksjoner 
iii. Pasientinformasjon/opplæring 
iv. Andre farmasøytiske tjenester? 
d) Har den nye ordningen påvirket hvilken informasjon dere gir til pasientene 
om legemidler?  
Oppsummering
Er dere fornøyde eller misfornøyde med at apoteket har begynt å levere multidose til 
hjemmesykepleien?  
Noe å tilføye?  
Takk-
SAMTALEGUIDE FASTLEGER 26.mars 2007 
Introduksjon ved Liv Johanne
- Hva er et fokusgruppeintervju
- Om gjennomføringen 
Implementering og organisasjonsutvikling 
Først i samtalen med dere vil vi høre hva dere synes om multidose og om dette har 
hatt noen innvirkning på deres daglige arbeide. 
1. Hvordan har innføringen av multidose gått? 
a) Hva er deres erfaring med innføringen av multidose? (godt/ikke godt) 
b) Hva synes dere om informasjonen dere fikk i forkant? Hva besto denne i? 
c) Er du godt kjent med de skriftlige prosedyrene til Trondheim kommune 
som omhandler multidose? Hva med hjemmesiden til Trondheim 
kommune som omhandler multiodoseprosjektet? 
2. Har multidose endret på fordeling av arbeidsoppgavene internt på legesenteret i 
forhold til oppfølging av pasientene som mottar hjemmesykepleie? 
a) Legesekretærenes oppgaver 
b) Dine oppgaver 
Bruk av EPJ og kommunikasjon 
Kommunikasjon og samarbeid har mye å si for hvor suksessfull 
informasjonsoverføringen er. Det er viktig at dere kommuniserer og samarbeider godt 
med hjemmesykepleiere og apotek for at pasienten skal få riktig medisin.  
3. Nå skal vi gå inn på tema om bruk av EPJ, og høre litt fra dere om samarbeidet 
mellom de ulike partene (hjemmesykepleie, apotek, legesekretærer og dere). 
a) Hvordan er informasjonsflyten mellom dere og hjemmesykepleien?  
b) Hvordan er informasjonsflyten mellom dere og apotekene?  
c) Hvordan er informasjonsflyten (samarbeidet) mellom dere og 
legesekretærene? 
d) Får du all informasjon du trenger? 
e) Får du gitt all nødvendig informasjon? 
f) Hva med kommunikasjonen kan forbedres? 
4. Hvordan brukes EPJ i kommunikasjonen?  
a) Dokumenteres legemiddelrelatert informasjon i lik grad nå som før i EPJ? 
b) Hvordan påvirker multidose bruken av medisinlisten i EPJ? 
c) Oppdaterer dere medisinlisten på samme måte som før?  (hvorfor/hvorfor 
ikke?) 
d) Har det endret seg hvor ofte og hvem som gjør oppgaven? 
e) Studere dere medisinkortet i samme grad som før? 
f) Har multidose ført til at andre deler (enn medisinlisten) av EPJ blir brukt mer 
eller mindre enn før? 
5. Hva er synet deres på dagens EPJ og hvordan synes dere at de/den fungerer? (i 
forhold til oversikt over pasientinformasjon og oppdatering?) 
Sikkerhet og tidsbruk 
Nå, som siste tema skal vi snakke om sikkerheten rundt multidose. Multidose ble 
innført for å bedre kvalitet i legemiddelhåndteringen og for å frigjøre sykepleiertid til 
andre oppgaver.
6. Hvordan mener dere bruken av multidose påvirker sikkerheten for pasientene i 
forhold til medisinering?
a) Har bidraget fra legene i forhold til sikkerhet blitt endret som følge av 
multidose? På hvilken måte? 
b) Hvilke feil har tidligere vært mest vanlig i forbindelse med medisinering?  
c) Har sjansen for å gjøre noen av disse feilene blitt redusert/forsvunnet? 
d) Har dere oppdaget nye muligheter for feil som kommer av det nye multidose 
systemet. Har dere eksempler på dette? 
e) Hvordan håndterer dere at noen pasienter skal ha noe medisin som ikke 
multidosesystemet tar seg av? Er dette blitt endret etter at multidose ble 
innført? 
7. Hvordan foregår oppdateringen av medisinlistene? 
a) Hvem gjør denne oppgaven? 
b) Når blir denne oppgaven gjort? (ved konsultasjoner, telefonkontakt om 
endringer fra hjemmesykepleien, apotek, sykehus, sykehjem eller andre, ved 
årskontroll…)
c) Føler dere dere trygge på at medisinlistene til enhver tid er oppdatert? 
8. Pasient- og pårørende- kontakt 
a) Har dere fått reaksjoner fra pasientene eller pårørende på multidose?  
b) Har den nye ordningen påvirket hvilken informasjon dere gir til pasientene om 
legemidler?  
9. Hvilke tanker har dere om videreføringen av multidose? 
Oppsummering 
Er dere fornøyde eller misfornøyde med at Trondheim kommune har tatt i bruk 
multidose?  
Noe å tilføye?  
Takk-
SAMTALEGUIDE HJEMMESYKEPLEIEN 6.mars 2007 
Introduksjon ved Marte
- Hva er et fokusgruppeintervju
- Om gjennomføringen 
Implementering og organisasjonsutvikling 
Først i samtalen med dere vil få rede på hva dere synes om multidose og om dette har 
hatt noen innvirkning i deres arbeid. 
1. Hvordan har innføringen av multidose gått? 
a) Hva er deres erfaring med innføringen av multidose? (godt/ikke godt) 
b) Hva synes dere om informasjonen dere fikk i forkant? 
c) Var du godt kjent med de skriftlige prosedyrene?  
2. Legemiddelhåndtering er i utgangspunktet en sykepleier og vernepleier oppgave. 
Har innføringen av multidose endret på fordelingen av oppgaver i håndteringen av 
legemidler? 
a) Multidoseansvarlig sin rolle? Er dette en rolle som vil bli opprettholdt eller 
er det naturlig at den forsvinner når multidose er ”oppe og går”? 
b) Da andre sykepleiernes sin rolle? 
c) Hjelpepleiere og omsorgsarbeidere med delegering sin rolle? 
d) Ufaglærte sin rolle? 
e) Enhetsleders innstilling til arbeidet med innføring av multidose? 
Bruk av Gerica og kommunikasjon 
Kommunikasjon og samarbeid har mye å si for hvor suksessfull 
informasjonsoverføringen er. Nå skal vi gå inn på tema om bruk av Gerica og høre litt 
fra dere om samarbeidet mellom de ulike partene (hjemmesykepleie, apotek og 
fastlegene) som berøres av multidose. 
3. Hvordan fungerer samarbeidet med dere, apotek og fastleger? 
a) Hvordan er informasjonsflyten dere i mellom? 
b) Hvordan brukes Gerica i kommunikasjonen?  
c) Får du all informasjon du trenger? 
d) Får du gitt all nødvendig informasjon? 
e) Dokumenteres legemiddelrelatert informasjon i lik grad nå som før i 
Gerica? 
f) Hva med kommunikasjonen kan forbedres? 
4. Hvordan påvirker multidose bruken av medisinkortet i Gerica? 
a) Oppdaterer dere medisinkortet på samme måte som før – hvorfor/hvorfor 
ikke?  
i. Har det endret seg hvor ofte og hvem som gjør oppgaven? 
ii. Studere dere medisinkortet like ofte som før? 
iii. Kunne oppgaven nå vært gitt til andre - kontorpersonell? 
iv. Har endret bruk av medisinkortet ført til at andre deler av 
Gerica blir brukt mer eller mindre enn før? 
5. Hvilken bruk og nytte har hjemmejournalen? Bruker dere hjemmejournalen aktivt? 
6. Ny teknologi og endringer i organisasjon og rutiner har ofte sine svakheter og 
mangler. Marte intro: (A-lag og B-lag på arbeidsplassen som følge av ulik mestring 
av data, bruk av post it lapper…) 
Hva vil dere si er svakheter og mangler med Gerica? Hva har dere gjort for å 
kompensere for dette?  
Sikkerhet og tidsbruk 
Nå, som siste tema skal vi snakke om sikkerheten rundt multidose. Multidose ble 
innført for å bedre kvalitet i legemiddelhåndteringen og for å frigjøre sykepleiertid til 
andre oppgaver.
7. Først her skal vi ta utgangspunkt i bedring av kvalitet i legemiddelhåndteringen. 
a) Hvilke feil har tidligere vært mest vanlig i forbindelse med medisinering?  
i. Har sjansen for å gjøre noen av disse feilene blitt redusert/forsvunnet? 
ii. Har dere oppdaget nye muligheter for feil som kommer av det nye 
multidose systemet. Har dere eksempler på dette? 
b) Har pasientene blitt bedre til å ta medisinen sin? Hvorfor/hvorfor ikke? På 
hvilken måte? 
c) Har dere fått reaksjoner fra pasientene eller pårørende på multidose? 
d) Hvordan er overensstemmelsen av medisinlistene til hjemmesykepleien og 
fastlegen i forhold til tidligere? 
e) Er dere tryggere på at pasienten får det han/hun skal ha nå enn tidligere? 
Hvorfor/hvorfor ikke?  
f) Hvordan håndterer dere at noen pasienter skal ha noe medisin som ikke 
multidosesystemet tar seg av? 
8. Nå skal vi diskutere den frigjorte sykepleiertiden og hva den blir brukt til. 
a) Bruker dere mer tid på pasientene? Hvorfor/hvorfor ikke? 
b) I hvilken grad benyttes ufaglærte i legemiddelhåndteringen? (mer/mindre)  
c) Dere doserer ikke legemidlene i like stor grad som før. Hvilke 
konsekvenser har det i forhold til å holde seg oppdatert på pasientenes 
medisiner og følge opp pasientene? 
i. Er oversikten over hva pasientene bruker av medisiner blitt bedre 
eller dårligere? 
ii. Er det blitt lettere eller vanskeligere å følge med på effekter og 
bivirkninger
iii. Har den nye ordningen påvirket hvilken informasjon dere gir til 
pasientene om legemidler?  
Oppsummering
Er dere fornøyd eller misfornøyde med at Trondheim kommune har tatt i bruk 
multidose?  
Noe å tilføye?  
Takk-
SAMTALEGUIDE LEGESEKRETÆRER, torsdag 22. mars 2007 
Introduksjon ved Marte
- Hva er et fokusgruppeintervju
- Om gjennomføringen 
Implementering og organisasjonsutvikling  
Først i samtalen med dere vil vi få rede på hva dere synes om multidose og hvordan  
innføringen av multidose har påvirket deres arbeidssituasjon. 
1. Hva vet dere om multidose? 
2. Hva er deres erfaring med oppstarten av multidose? (godt/ikke godt)  
3. Har dere en egen legesekretær som er ansvarlig for å ivareta dialogen med 
pasientene og hjemmesykepleien ved bestillinger av medisiner? Hva er i så fall 
denne personen sin oppgave? 
4. Har multidose endret på fordeling av arbeidsoppgavene internt på legesenteret i 
forhold til oppfølging av pasientene som mottar hjemmesykepleie? 
a. Legenes oppgaver 
b. Deres oppgaver 
5. Hvor godt kjent er du med de skriftlige prosedyrene til Trondheim kommune som 
omhandler multidose? Hva med internettsiden til Trondheim kommune som 
omhandler multidose? 
6. Har dere skriftliggjorte rutiner på legekontoret som omhandler 
medikamentbestillinger, om multidose, andre faste medisiner og om 
eventuellmedisiner 
Samarbeid og kommunikasjon 
Kommunikasjon og samarbeid har mye å si for hvor suksessfull 
informasjonsoverføringen er. Nå skal vi gå inn på tema om overføring av 
informasjon. 
6. Hvilken informasjon og opplæring har dere fått om multidose? 
 7. Vi vil også høre om samarbeidet mellom de ulike partene (hjemmesykepleie, 
apotek, legesekretærer og fastlegene) som berøres av multidose. 
a) Hvordan er informasjonsflyten internt på legekontoret (mellom 
legesekretærene og med legen) når det gjelder håndtering av 
multidosebrukerne? 
b) Hvordan er informasjonsflyten mellom dere og hjemmesykepleien? 
c) Hvordan er informasjonsflyten mellom dere og apotekene? 
d) Får du all den informasjonen du trenger? (for mye, for lite) 
e) Får du gitt videre all den informasjonen du vil? 
f) Hva med samarbeid og kommunikasjon kan forbedres? 
Sikkerhet og tidsbruk 
8. Hvordan mener dere bruken av multidose påvirker sikkerheten for pasientene i 
forhold til medisinering? Har bidraget fra legekontoret i forhold til sikkerhet blitt 
endret som følge av multidose? (Hvorfor/Hvorfor ikke?) 
9. Hvordan foregår oppdateringen av medisinlistene? 
i. Hvem gjør denne oppgaven? 
ii. Når blir denne oppgaven gjort? (ved konsultasjoner, telefonkontakt om 
endringer fra hjemmesykepleien, apotek, sykehus, sykehjem eller andre, 
ved årskontroll…)
iii. Blir endringer som skrives inn i medisinlisten kontrollerte? (Evt av hvem?) 
iv. Føler dere dere trygge på at medisinlistene til enhver tid er oppdatert? 
10. Har dere fått reaksjoner fra pasientene eller pårørende på multidose?  
11. Hvordan påvirker multidose tidsbruken på legekontoret? 
Oppsummering
Er dere fornøyde eller misfornøyde med at Trondheim kommune har begynt 
multidose?  
Noe å tilføye?  
Takk-
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Samtykkebasert elektronisk legemiddelkort i Tromsø
Til alle fastleger i Tromsø kommune
Samarbeid mellom fastlegene og hjemmetjenesten om medisinering av felles pasienter
Alder:   år
Arbeidssted:
Antall pasienter på fastlegeliste:   personer
Hvor lenge har du jobbet i allmennpraksis?   år
Er du spesialist i allmennmedisin?
Type praksis:
1. Hvor mange soner innen hjemmesykepleien
vil du anslå at du har pasienter felles med? soner
2. Fremgår det tydelig av journalen at hjemme sykepleien
har overtatt håndtering av medikamenter?
3. Hvordan foregår reseptforskrivningen til hjemmesykepleien sine pasienter?
a. Hvordan mottar du bestilling av
resepter fra hjemmesykepleien:
b. Hvem fyller vanligvis ut resepter som
bestilles av hjemmesykepleien?
Evt.kommentarer:
c. Bruker du å kontrollere bestillingen mot opplysninger i journalen?
d. Hvordan leveres eller sendes vanligvis de ferdige reseptene?
4. Benytter du deg av muligheten til å skrive ut og sende
med et medisinkort fra journalen når medisineringen blir endret?
Ja Nei
Enlegepraksis Flerlegekontor/praksisfellesskap
Alltid
Som regel
Noen ganger
Aldri
Muntlig/per telefon
Skriftlig
Legen
Medarbeider
Rutinemessig
Bare ved tvil, og evt. ved spørsmål/oppfordring fra medarbeider
Blir sendt til eller hentet av hjemmesykepleien
Blir sendt til pasienten selv eller til pårørende
Sendes til apoteket i posten
Fakses til apoteket
Alltid
Som regel
Noen ganger
Aldri
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5. Hvilke rutiner har du for å oppdatere hjemmesykepleien
på endringer i medisinforskrivning når det gjelder dine pasienter?
6. Hvilke rutiner har du for å oppdatere hjemmesykepleien på endringer i medisinforskrivning
når det gjelder pasienter du behandler under legevakt?
7. Hvis du ser bort fra epikriser, blir du oppdatert av hjemmesykepleien når andre leger gjør
endringer i medisinforskriving?
8. Oppdaterer du "faste medisiner"
fortløpende i ditt journalsystem?
Kommentarer:
9. Når pasienten har behov for hjelp med medisinhåndteringen og
hjemmesykepleien overtar ansvaret for utdelingen av medisin:
a. inngår du skriftlig avtale med pasienten og
hjemmetjenesten
b. Vurderer du pasientens samtykkekompetanse
før avtale inngås?
c. Hvem forholder du deg til hvis pasienten ikke har samtykkekompetanse?
Hjemmesykepleien blir rutinemessig kontaktet per telefon/får beskjed skriftlig ved endringer
Hjemmesykepleien blir vanligvis oppdatert gjennom reseptene som utskrives
Gir vanligvis beskjed via pasienten eller pårørende
Ved hjelp av kommunikasjonsark/hjemmejournal
Annet
Hjemmesykepleien blir rutinemessig kontaktet per telefon/får beskjed skriftlig
Hjemmesykepleien blir vanligvis oppdatert gjennom reseptene som utskrives
Gir vanligvis beskjed gjennom pasienten eller pårørende
Ved hjelp av kommunikasjonsark/hjemmejournal
Annet
Deltar ikke på legevakt
eller muntlig ved endringer
Legekontoret blir rutinemessig kontaktet og oppdatert om nye forskrivninger og endringer
Jeg blir oppdatert om andres forskrivninger i ettertid i møter med hjemmesykepleien
Journalen blir bare oppdatert ved at resepter utskrives
Annet
Alltid
Som regel
Noen ganger
Aldri
Alltid
Som regel
Noen ganger
Aldri
Alltid
Som regel
Noen ganger
Aldri
Nærmeste pårørende Hjelpeverge Tar beslutningen selv Andre
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10.Hvilke rutiner har legekontoret for kommunikasjon med
hjemmesykepleien vedrørende dosering av Marevan?
11.Hvilke rutiner har legekontoret for kommunikasjon
med hjemmesykepleien vedrørende blodprøveresultater
Det skjer som oftest bare per telefon/muntlig
Informasjon utveksles vanligvis bare skriftlig/bruk av doseringskort
Informasjon formidles både skriftlig og muntlig
Annet
Det skjer som oftest bare muntlig eller per telefon
Informasjon utveksles vanligvis bare skriftlig
Informasjon formidles både skriftlig og muntlig
Annet
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Samtykkebasert elektronisk medisinkort i Trondheim
Til alle fastleger i Trondheim kommune
Samarbeid mellom fastlegene og hjemmetjenesten om medisinering av felles pasienter
Alder:   år
Arbeidssted:
Antall pasienter på fastlegeliste:   personer
Hvor lenge har du jobbet i allmennpraksis?   år
Er du spesialist i allmennmedisin?
Type praksis:
1. Hvor mange soner innen hjemmesykepleien
vil du anslå at du har pasienter felles med? soner
2. Fremgår det tydelig av journalen at hjemme sykepleien
har overtatt håndtering av medikamenter?
3. Hvordan foregår reseptforskrivningen til hjemmesykepleien sine pasienter?
a. Hvordan mottar du bestilling av
resepter fra hjemmesykepleien:
b. Hvem fyller vanligvis ut resepter som
bestilles av hjemmesykepleien?
Evt.kommentarer:
c. Bruker du å kontrollere bestillingen mot opplysninger i journalen?
d. Hvordan leveres eller sendes vanligvis de ferdige reseptene?
4. Benytter du deg av muligheten til å skrive ut og sende
med et medisinkort fra journalen når medisineringen blir endret?
Ja Nei
Enlegepraksis Flerlegekontor/praksisfellesskap
Alltid
Som regel
Noen ganger
Aldri
Muntlig/per telefon
Skriftlig
Legen
Medarbeider
Rutinemessig
Bare ved tvil, og evt. ved spørsmål/oppfordring fra medarbeider
Blir sendt til eller hentet av hjemmesykepleien
Blir sendt til pasienten selv eller til pårørende
Sendes til apoteket i posten
Fakses til apoteket
Alltid
Som regel
Noen ganger
Aldri
Draft
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5. Hvilke rutiner har du for å oppdatere hjemmesykepleien
på endringer i medisinforskrivning når det gjelder dine pasienter?
6. Hvilke rutiner har du for å oppdatere hjemmesykepleien på endringer i medisinforskrivning
når det gjelder pasienter du behandler under legevakt?
7. Hvis du ser bort fra epikriser, blir du oppdatert av hjemmesykepleien når andre leger gjør
endringer i medisinforskriving?
8. Oppdaterer du "faste medisiner"
fortløpende i ditt journalsystem?
Evt.kommentarer:
9. Når pasienten har behov for hjelp med medisinhåndteringen og
hjemmesykepleien overtar ansvaret for utdelingen av medisin:
a. Ber du om pasientens samtykke til at du tar kontakt med
forvaltningskontoret for kommunalt vedtak på bistand?
b. Vurderer du samtykkekompetanse før du tar kontakt?
c. Hvem forholder du deg til hvis pasienten ikke har samtykkekompetanse?
Hjemmesykepleien blir rutinemessig kontaktet per telefon/får beskjed skriftlig ved endringer
Hjemmesykepleien blir vanligvis oppdatert gjennom reseptene som utskrives
Gir vanligvis beskjed via pasienten eller pårørende
Ved hjelp av kommunikasjonsark/hjemmejournal
Annet
Hjemmesykepleien blir rutinemessig kontaktet per telefon/får beskjed skriftlig
Hjemmesykepleien blir vanligvis oppdatert gjennom reseptene som utskrives
Gir vanligvis beskjed gjennom pasienten eller pårørende
Ved hjelp av kommunikasjonsark/hjemmejournal
Annet
Deltar ikke på legevakt
eller muntlig ved endringer
Legekontoret blir rutinemessig kontaktet og oppdatert om nye forskrivninger og endringer
Jeg blir oppdatert om andres forskrivninger i ettertid i møter med hjemmesykepleien
Journalen blir bare oppdatert ved at resepter utskrives
Annet
Alltid
Som regel
Noen ganger
Aldri
Alltid
Som regel
Noen ganger
Aldri
Alltid
Som regel
Noen ganger
Aldri
Nærmeste pårørende Hjelpeverge Tar beslutningen selv Andre
Draft
Innføring av multidosepakkede legemidler i Trondheim
Samtykkebasert elektronisk medisinkort i Trondheim
10.Hvilke rutiner har legekontoret for kommunikasjon med
hjemmesykepleien vedrørende dosering av Marevan?
11.Hvilke rutiner har legekontoret for kommunikasjon
med hjemmesykepleien vedrørende blodprøveresultater
12.Du har nå mottatt informasjon om multidosepakkede legemidler og hvordan dette vil kunne
påvirke ditt samarbeide med hjemmesykepleien og apotek angående medisineringen av
felles pasienter. Hvilke endringer mener du det nye doseringssystemet vil kunne medføre?
Mer Uendret   Mindre
Oversikt over pasientenes legemidler          
Feilmedisinering
Samarbeid med hjemmesykepleien
Arbeid for legen
Arbeid for medarbeider
Arbeid for hjemmesykepleien
Kassasjon av legemidler          
Ser du andre fordeler eller ulemper med systemet?
13.Du har også mottatt informasjon om Fyrtårnsprosjektet i Trondheim og innføringen av
samtykkebaserte elektroniske medisinkort. Hvilke endringer mener du denne nye
løsningen vil kunne medføre?
Mer   Uendret  Mindre
Oversikt over pasientenes legemidler          
Feilmedisinering          
Samarbeid med hjemmesykepleien          
Arbeid for legen          
Arbeid for medarbeider          
Arbeid for hjemmesykepleien          
Fare for brudd på taushetsplikten          
Ser du andre fordeler eller ulemper med systemet?
Det skjer som oftest bare per telefon/muntlig
Informasjon utveksles vanligvis bare skriftlig/bruk av doseringskort
Informasjon formidles både skriftlig og muntlig
Annet
Det skjer som oftest bare muntlig eller per telefon
Informasjon utveksles vanligvis bare skriftlig
Informasjon formidles både skriftlig og muntlig
Annet
Draft
Samtykkebasert elektronisk legemiddelkort i Tromsø
  Oppfølgingsstudie av rutiner
Til alle fastleger i Tromsø kommune
Samarbeid mellom fastlegene og hjemmetjenesten om medisinering av felles pasienter
Alder:   år
Kjønn:
Antall pasienter på fastlegeliste:   personer
Hvor lenge har du jobbet i allmennpraksis?   år
Er du spesialist i allmennmedisin?
1. Hvor mange soner innen hjemmetjenesten vil du anslå at du har pasienter felles med?
Merking i journal
2. Fremgår det tydelig av journalen at hjemmetjenesten har overtatt håndtering av 
medikamenter for pasienten?
Resepthåndtering
3. Spørsmål angående resepthåndtering
a. Hvordan mottar du bestilling av resepter? (flere kryss mulig)
b. Hvem fyller vanligvis ut resepter som bestilles av hjemmetjenesten?
Evt.kommentarer:
Ja Nei
Alltid Som regel Noen ganger Aldri
Muntlig/per telefon fra hjemmetjenesten
Skriftlig/fax fra hjemmetjenesten
Muntlig/per telefon fra apoteket
Skriftlig/fax fra apoteket
Legen
Medarbeider
Kvinne Mann
1-5 6-10 mer enn 10
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  Oppfølgingsstudie av rutiner
c. Bruker du å kontrollere bestillingen mot opplysninger i journalen?
d. Hvordan leveres eller sendes vanligvis de ferdige reseptene? (flere kryss mulig)
Kommunikasjon om endringer i medisineringen
4. Informasjon om endringer i medisinering
a. Pleier du å skrive ut og sende med pasienten en medisinliste fra journalen når endringer
    gjøres under konsultasjon?
b. Kontakter du hjemmetjenesten ved endringer?
  c. Kontaktform til hjemmetjenesten (flere kryss mulig)
d. Kontakter du apoteket ved endringer?
5. Hvilke rutiner har du for å oppdatere hjemmetjenesten på endringer i 
medisinforskrivningen når det gjelder pasienter du behandler under legevakt?
(flere kryss mulig)
  Hjemmetjenesten blir rutinemessig kontaktet per telefon/får beskjed skriftlig eller 
muntlig ved endringer
  Hjemmetjenesten blir vanligvis oppdatert gjennom reseptene som utskrives
  Gir vanligvis beskjed gjennom pasienten eller pårørende
  Overlater vanligvis til fastlegen å informere om endringer
  Ved hjelp av kommunikasjonsark/hjemmejournal
  Annet
  Deltar ikke på legevakt
Hentes av- eller sendes/leveres hjemmetjenesten
Sendes til pasienten selv eller pårørende
Sendes eller fakses til apoteket
Rutinemessig
Bare ved tvil, og evt. ved spørsmål/oppfordring fra medarbeider
Alltid Som regel Noen ganger Aldri
Rutinemessig Som regel Noen ganger Aldri
Per telefon
Får beskjed skriftlig ved endringer
Gjennom reseptene som utskrives
Beskjed via pasienten eller pårørende
Ved hjelp av kommunikasjonsark/hjemmejournal
Annet
Rutinemessig Som regel Noen ganger Aldri
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  Oppfølgingsstudie av rutiner
6. Hvis du ser bort fra epikriser, blir du oppdatert av hjemmetjenesten når andre leger gjør
endringer i medisinforskriving? (flere kryss mulig)
  Legekontoret blir rutinemessig kontaktet og oppdatert om nye forskrivninger og
endringer
Jeg blir oppdatert om andres forskrivninger i ettertid i møter med hjemmetjenesten
Journalen blir bare oppdatert ved at resepter skal fornyes
Annet
7. Oppdaterer du "faste medisiner" fortløpende i ditt journalsystem?
Evt.kommentarer:
8. Hvilke rutiner har legekontoret for kommunikasjon med hjemmetjenesten vedrørende 
dosering av Marevan? (flere kryss mulig)
  Det skjer som oftest bare per telefon/muntlig
  Informasjon utveksles vanligvis bare skriftlig/bruk av doseringskort
  Informasjon formidles både skriftlig og muntlig til hjemmetjenesten
  Informasjon formidles både skriftlig og muntlig til apoteket
  Annet
Alltid Som regel Noen ganger Aldri
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Til alle fastleger i Trondheim kommune
Samarbeid mellom fastlegene og hjemmetjenesten om medisinering av felles pasienter
Alder:   år
Kjønn:
Antall pasienter på fastlegeliste:   personer
Hvor lenge har du jobbet i allmennpraksis?   år
Er du spesialist i allmennmedisin?
1. Hvor mange soner innen hjemmetjenesten vil du anslå at du har pasienter felles med?
2. Hvor mange av dine pasienter vil du anslå mottar multidose?
Merking i journal
3. For de pasientene som ikke mottar multidose: Fremgår det tydelig av journalen at
hjemmetjenesten har overtatt håndtering av medikamenter for pasienten?
4. For pasienter som har tatt i bruk multidose: Fremgår det tydelig av journalen at
vedkommende er multidosebruker?
Resepthåndtering
5. Spørsmål angående resepthåndtering til pasienter som ikke bruker multidose
a. Hvordan mottar du bestilling av resepter (Flere kryss mulig)
b. Hvem fyller vanligvis ut resepter som bestilles av hjemmetjenesten?
Evt.kommentarer:
Ja Nei
Alltid Som regel Noen ganger Aldri
Muntlig/per telefon fra hjemmetjenesten
Skriftlig/fax fra hjemmetjenesten
Muntlig/per telefon fra apoteket
Skriftlig/fax fra apoteket
Legen
Medarbeider
Kvinne Mann
1-5 6-10 mer enn 10
Ingen 1-5 6-10 mer enn 10
Alltid Som regel Noen ganger Aldri
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c. Bruker du å kontrollere bestillingen mot opplysninger i journalen?
d. Hvordan leveres eller sendes vanligvis de ferdige reseptene? (flere kryss mulig)
6. Spørsmål angående resepthåndtering til pasienter som har tatt i bruk multidose
a) Hvem skriver vanligvis ut medisinlisten (gjelder som resept) som bestilles av apoteket?
Evt.kommentarer:
b) Bruker du å kontrollere medisinlisten mot opplysninger i journalen?
c) Hvordan leveres eller sendes vanligvis medisinlistene?
Kommunikasjon om endringer i medisineringen
7. Informasjon om endringer i medisinering av pasienter som ikke bruker multidose
a. Pleier du å skrive ut og sende med pasienten en medisinliste fra journalen når endringer
    gjøres under konsultasjon?
b. Kontakter du hjemmetjenesten ved endringer?
Hentes av- eller sendes/leveres hjemmetjenesten
Sendes til pasienten selv eller pårørende
Sendes eller fakses til apoteket
Alltid Som regel Noen ganger Aldri
Rutinemessig
Bare ved tvil, og evt. ved spørsmål/oppfordring fra medarbeider
Legen
Medarbeider
Rutinemessig
Bare ved tvil, og evt. ved spørsmål/oppfordring fra medarbeider
Sendes til apoteket i posten
Fakses til apoteket
Annet:
Rutinemessig Som regel Noen ganger Aldri
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c. Kontaktform til hjemmetjenesten (flere kryss mulig)
d. Kontakter du apoteket ved endringer?
8. Informasjon om endringer i medisinering av pasienter som har tatt i bruk multidose
a. Pleier du å skrive ut og sende med pasienten en medisinliste fra journalen når endringer
    gjøres under konsultasjon?
b. Kontakter du hjemmetjenesten ved endringer?
c. Kontaktform til hjemmetjenesten (flere kryss mulig)
d. Kontakter du apoteket ved endringer?
9. Hvilke rutiner har du for å oppdatere hjemmetjenesten på endringer i medisinforskrivningen 
når det gjelder pasienter du behandler under legevakt? (flere kryss mulig)
  Hjemmetjenesten blir rutinemessig kontaktet per telefon/får beskjed skriftlig eller 
muntlig ved endringer
  Hjemmetjenesten blir vanligvis oppdatert gjennom reseptene som utskrives
  Gir vanligvis beskjed gjennom pasienten eller pårørende
  Overlater vanligvis til fastlegen å informere om endringer
  Ved hjelp av kommunikasjonsark/hjemmejournal
  Annet
  Deltar ikke på legevakt
Rutinemessig Som regel Noen ganger Aldri
Per telefon
Får beskjed skriftlig ved endringer
Gjennom reseptene som utskrives
Beskjed via pasienten eller pårørende
Ved hjelp av kommunikasjonsark/hjemmejournal
Annet
Alltid Som regel Noen ganger Aldri
Rutinemessig Som regel Noen ganger Aldri
Per telefon
Får beskjed skriftlig ved endringer
Gjennom reseptene som utskrives
Beskjed via pasienten eller pårørende
Ved hjelp av kommunikasjonsark/hjemmejournal
Annet
Rutinemessig Som regel Noen ganger Aldri
7601
Innføring av multidosepakkede legemidler i Trondheim
10.Hvis du ser bort fra epikriser, hvordan blir du oppdatert når andre leger gjør endringer i
medisinforskriving til pasienter som ikke bruker multidose? (flere kryss mulig)
  Jeg blir rutinemessig kontaktet og oppdatert om nye forskrivninger og endringer av
hjemmetjenesten
  Jeg blir rutinemessig kontaktet og oppdatert om nye forskrivninger og endringer av
apoteket
  Jeg blir oppdatert om andres forskrivninger i ettertid i møter med hjemmetjenesten
Annet
11.Hvis du ser bort fra epikriser, hvordan blir du oppdatert når andre leger gjør endringer i
medisinforskriving til multidosepasienter? (flere kryss mulig)
  Jeg blir rutinemessig kontaktet og oppdatert om nye forskrivninger og endringer fra
hjemmetjenesten
  Jeg blir rutinemessig kontaktet og oppdatert om nye forskrivninger og endringer av
apoteket
  Jeg blir oppdatert om andres forskrivninger i ettertid i møter med hjemmetjenesten
  Annet 
12.Oppdaterer du "faste medisiner" fortløpende i ditt journalsystem?
Evt.kommentarer:
13.For multidosebrukere: Hvilken doseringsmåte er mest vanlig for Marevan i din praksis?
14.For pasienter som ikke bruker multidose: Hvilke rutiner har legekontoret for 
kommunikasjon med hjemmetjenesten vedrørende dosering av Marevan?
(flere kryss mulig)
  Det skjer som oftest bare per telefon/muntlig
  Informasjon utveksles vanligvis bare skriftlig/bruk av doseringskort
  Informasjon formidles både skriftlig og muntlig til hjemmetjenesten
  Informasjon formidles både skriftlig og muntlig til apoteket
  Annet
Alltid Som regel Noen ganger Aldri
I multidose I dosett
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15.For pasienter som får Marevan i multidosepakning: Hvilke rutiner har legekontoret for
kommunikasjon med hjemmetjenesten vedrørende dosering av Marevan?
(flere kryss mulig)
  Det skjer som oftest bare per telefon/muntlig
  Informasjon utveksles vanligvis bare skriftlig/bruk av doseringskort
  Informasjon formidles både skriftlig og muntlig til hjemmetjenesten
  Informasjon formidles både skriftlig og muntlig til apoteket
  Annet
16.Hvilke endringer mener du multidose har medført?
Mer Uendret   Mindre
Oversikt over pasientenes legemidler
         
Feilmedisinering
         
Samarbeid med hjemmetjenesten
         
Samarbeide med apoteket
         
Arbeid for legen
         
Arbeid for medarbeider
         
Arbeid for hjemmetjenesten
         
Kassasjon av legemidler
17.I hjemmetjenesten i Trondheim gjøres all forskrivning av legemidler til multidose av
fastlegen. Hvem mener du bør kunne forskrive legemidler for multidose? (Flere kryss
mulig)
Fastlegen (og fastlegens vikar)
    Legevaktslege
    Sykehuslege ved utskrivning
    Sykehjemslege ved utskrivning
    Privatpraktiserende spesialist
    Annen tilfeldig lege
Kommentarer:
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18.Ser du andre fordeler eller ulemper med multidosesystemet?
19.Vil du foretrekke fortsatt bruk av multidose i hjemmetjenesten i fremtiden?
Hvorfor/hvorfor ikke?
Ja Nei Vet ikke
7601
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 ORIGINAL ARTICLE 
 Early experiences with the multidose drug dispensing 
system – A matter of trust? 
 LIV JOHANNE  WEKRE 1,2,3 ,  LINE  MELBY 3  &  ANDERS  GRIMSMO 1,3 
 1 Department of Community Medicine and General Practice, Norwegian University of Science and Technology (NTNU), 
Trondheim, Norway,  2 Central Norway Hospital Pharmacy Trust, Trondheim,  3 Norwegian EHR Research Centre, 
Norwegian University of Science and Technology (NTNU), Trondheim, Norway 
 Abstract 
 Objective. To study early experiences with multidose drug dispensing (MDD) among different groups of health personnel. 
 Design. Qualitative study based on focus-group interviews.  Setting. Primary health care, Trondheim, Norway.  Main outcome. 
The importance of trust in the technology and in collaborating partners is actualized in the early implementation of MDD. 
 Results. GPs, home-care nurses, pharmacists, and medical secretaries trusted the new MDD technology. The quality of the 
GPs ’ medication records improved. However, health personnel, including the GPs themselves, would not always trust the 
medication records of the GPs. Checking the multidose bags arriving from the pharmacy was considered unnecessary in 
the written routines dealing with MDD. However, home-care nurses experienced errors and continued to manually check 
the bags. Nurses in the home-care service felt a loss of knowledge with regard to the patients ’ medications and in turn 
experienced reduced ability to give medical information to patients and to observe the effects of the drugs. The home-care 
services ’ routines for drug handling were not always trusted by the other groups of health personnel involved.  Conclusion. 
Health personnel faced some challenges during the implementation of the MDD system, but most of them remained 
conﬁ dent in the new system. Building trust has to be a process that runs in parallel with the introduction of 
new technology and the establishment of new routines for improving the quality in handling of medicines and to facilitate 
better cooperation and communication. 
 Key Words:  Drug packaging ,  family practice ,  home-care services ,  information sharing ,  medication errors ,  medication records , 
 pharmacy ,  trust 
 Multidose drug dispensing (MDD) is a  “ new ” expansive 
ﬁ eld in the Scandinavian countries, both in the 
community care settings and in the nursing home 
setting. MDD is recommended by health authori-
ties, motivated by expected savings in terms of med-
ication dispensing errors and drug expenses [1 – 3]. 
However, scientiﬁ c evaluations are missing [3,4]. 
MDD implies that the patient receives drugs 
machine-dispensed into one unit for each dose occa-
sion, packed in disposable bags. The dose unit bags 
are labelled with patient data, drug contents data, 
and time for intake [5 – 7]. 
 MDD was implemented in the home-care 
services in Trondheim, Norway, in 2006. The 
implementation was accomplished in a complex 
organization including pharmacies, home-care services, 
and GPs ’ ofﬁ ces. At the time of implementation the 
home-care services were organized into 27 home-
care divisions in four town districts. A total of 137 GPs 
participated, and ﬁ ve pharmacies were involved as 
MDD providers. The home-care service adminis-
trated drugs for approximately 1800 out of 3000 
patients receiving home-care. One of the major sup-
pliers of multidose drugs in Norway was responsible 
for the production of the new drug packages and 
distributing them to the pharmacies. In addition to 
dispensing the patients ’ multidose drugs to the dif-
ferent home-care divisions, the pharmacies were also 
charged with updating the medication record in the 
multidose provider ’ s database and making reviews of 
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the patients ’ prescriptions whenever changes were 
made by the GP (in addition to an annual review). 
 A project group was appointed to prepare and 
assist the implementation process. Information dis-
semination was emphasized to create involvement, 
motivation, and commitment among the users. It was 
also requested that the home-care divisions and the 
pharmacies appointed a speciﬁ c MDD contact per-
son to function as a contact point for the different 
organizations. 
 Unlike most other municipalities using MDD in 
Norway, Trondheim decided to use the GP ’ s medica-
tion record in the electronic health record (EHR) as 
the master medication record. Hence, other health 
personnel had to update the medication record in 
their own EHR in accordance with the GP ’ s medica-
tion record. Only the patient ’ s GP was allowed to 
prescribe drugs to be included in the multidose drug 
packages. 
 The aim of this project was to study early experi-
ences amongst the different groups of health profes-
sionals participating in the implementation of the 
MDD system. Several signiﬁ cant issues were brought 
up during the interview sessions but, already at an 
early stage of analysing the data, trust stood out as 
an important concern in all groups. In this article we 
have explored in depth the users ’ experiences with 
the MDD related to trust  – in terms of both trust in 
the MDD system and trust within and between 
groups of collaborating health personnel. The users ’ 
experiences with the MDD system covered the han-
dling of drugs from prescribing to administration of 
drugs to the patient. 
 Material and methods 
 Four focus-group interviews were carried out in 
March 2007, about one year after the introduction of 
MDD. We performed a careful selection of health 
personnel with varied MDD experience; the selection 
spanned different workplaces and personnel with 
different roles in the handling of MDD, thus obtain-
ing data-source triangulation [8]. The four groups 
contained six home-care nurses, ﬁ ve pharmacists, six 
GP medical secretaries, and seven GPs. The focus-
group interviews lasted from 70 to 110 minutes. 
 A master ’ s student in sociology, trained in con-
ducting focus-group interviews, opened and moder-
ated the interviews. The moderator used an interview 
guide tailored to each group, but with some themes 
common to all of the groups (Table I). During the 
interviews the informants shared experiences and 
reﬂ ections related to the implementation and use of 
MDD. The interviews were observed and videotaped 
by the ﬁ rst author. Afterwards the interviews were 
transcribed verbatim by the moderator and checked 
by the ﬁ rst author. 
 Data were analysed by the authors through sys-
tematic text condensation, an approach described 
by Giorgi [9] and modiﬁ ed by Malterud [10]. We 
started the analysis by using the themes from the 
interview guide as point of departure for deﬁ ning 
key categories. However, the issue of trust distin-
guished itself as a theme that was raised by many of 
our informants. This led us to adopt trust as a gov-
erning idea throughout the analysis. This emphasis 
on trust from the informants when reﬂ ecting on 
their experiences with MDD is thus a result in itself, 
but was also used to structure our analysis. 
 Observation triangulation was achieved through 
independent analysis of the transcribed interviews by 
 Table I. Themes in the interview guides and example questions from the focus-group interviews. 
Themes Example questions
Implementation and organizational development How did the implementation of multidose progress?
How did the implementation change the distribution of work at your workplace?
Cooperation and communication How is the ﬂ ow of information between you and the home-care service? (question 
directed to doctors, medical secretaries, and pharmacists)
What can be improved with regard to communication?
Patient safety and time use In what way does use of the multidose dispensed drugs inﬂ uence patient safety?
Do you take up more time on patients after the implementation of MDD? Why/
why not? (question directed to nurses in the home-care services)
Trust is an important issue for health personnel 
in an early phase of the implementation of a mul-
tidose drug dispensing (MDD) system:
Trust in the MDD system was challenged  •
by medication records being outdated and 
the loss of ﬂ exibility in choosing and dosing 
drugs.
Changes in routines and roles required a  •
higher level of trust between professionals.
Home-care nurses feared a loss of compe- •
tence in following up patients and drug 
effects because of reduced time spent on 
medications.
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the three authors [8]. The ﬁ rst and third author have 
extensive clinical experience in the ﬁ eld as a commu-
nity pharmacist and former GP, respectively. In addi-
tion the second and third author have experience 
from research on collaboration in health care as 
respectively a social scientist and a public health 
researcher. 
 Results 
 Trust  – both in the MDD system and in colleagues – was 
a central issue for all the informants when discussing 
their experiences related to MDD. 
 Trust in the MDD system 
 Most of the participants expressed positive atti-
tudes towards the MDD system, and frequently  – 
either directly or indirectly  – related it to trust. In 
general it was expected that the MDD system 
would lead to more trustworthy handling of drugs 
and fewer dispensing errors, as illustrated by the 
following quote: 
 I know someone  … who told me that the mother 
became completely healthy when she began with 
this [multidose dispensed drugs]. She stopped the 
stumbling and lurching and everything. So it turns 
out that she must have been mixing. She became a 
new person … . Because when she got what she was 
supposed to get, at the right time  … it didn ’ t take 
long  … before they said,  “ now, she is in such good 
health ” . (Medical secretary) 
 However, one of the nurses explained that they 
kept on checking the multidose drug packages as 
they arrived from the pharmacy. This was done 
even though it was considered unnecessary in the 
written routines handed out with the implementa-
tion of MDD and may indicate that they did not 
really have complete trust in the MDD system 
after all. 
 Prescriptions of drugs with an interim change 
in dosage and as an interim cure were considered 
problematic in the MDD system, as was handling of 
warfarin: 
 … when it comes to short adjustments of medications 
and adjustments of furosemide in a short period or 
a cure, it is in many cases more difﬁ cult to go through 
with after the implementation of MDD. (GP) 
 I think warfarin has been a difﬁ cult thing. I had 
a patient who had an incorrect warfarin dosage 
for eight weeks due to failure in MDD. And what 
happened I do not really know  … (GP) 
 The quotes indicate that the MDD system is 
perceived as less ﬂ exible when it comes to changes 
in medication/dosage than the old, manual system. 
 Moreover, all the groups of health personnel faced 
an increased need for cooperation and communication 
among themselves during the implementation of MDD. 
The fact that the MDD system required more com-
munication and stronger involvement of the GPs and 
in particular the pharmacies can be interpreted as 
caused by health personnel not completely trusting the 
system. One of the GPs said that he regarded  “ the phar-
macy as a safety net in terms of dosages to patients ” , 
illustrating the important role of the pharmacy in creat-
ing a trustworthy system for MDD. 
 Trust among the other groups of health personnel 
 Errors made in the home-care service after the imple-
mentation of MDD were reported both by pharma-
cists and by GPs. 
 In the case I was talking about, it was one 
[a home-care nurse] who gave an antidepressant 
that was discontinued. The doctor thought he ’ d try 
a new type, which was packaged in the MDD, 
but the home-care gave the other in addition. 
(Pharmacist) 
 These and similar observations challenged the trust 
in the routines of the home-care services. The coop-
erating professions did not always trust the GP ’ s 
updates to the medication record either. The medica-
tion records were needed for prescriptions of multi-
dose drugs. Home-care nurses experienced difﬁ culties 
with getting in touch with GPs in order to make them 
update and hand over medication records. 
 [Cooperation with] the pharmacies works very 
smoothly. Doctors, too, but it takes time … . That ’ s the 
problem; they may not call back. (Nurse) 
 The GPs and the medical secretaries conﬁ rmed the 
problems and blamed insufﬁ cient information and 
follow-up from the project group responsible for 
implementation. The pharmacists also experienced 
insufﬁ cient updates of the medication records by the 
GPs. 
 I called the doctor and received the prescription over 
the phone. Next time we got it [the medication record] 
the doctor had not changed it. The doctor only said 
yes on the phone … . That ’ s why we agreed to get 
everything [new prescriptions] in writing. The doctor 
now faxes us. (Pharmacist) 
 GPs and nurses stated that the implementation of 
MDD led to an increased dialogue between them 
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concerning which drugs should be adminis tered 
 “ as required ” (pro re nata). For practical reasons 
the home-care wanted as much as possible to be 
packed in the multidose bags while the GPs often 
wanted some drugs, such as sleeping pills, to be 
taken only when required. Both parties were 
 content with this increased level of dialogue, as it 
in the end is beneﬁ cial to the welfare of the 
patient. 
 Trust within the different groups of health personnel 
 The home-care nurses were concerned about the 
reduction in manual dispensing of drugs. They feared 
that this would decrease their knowledge of patients ’ 
health in relation to his/her drug intake, and make 
them, as a group, less trusted concerning these ques-
tions. A nurse said: 
 I guess we had better overview before [the introduc-
tion of MDD] … . Now, of course we have lost it, and 
then I think in the long run I will lose the overview 
over the patient ’ s condition … . Also, when you sit and 
dose medicines manually, you think and reﬂ ect on 
the patient you are dosing for … . Then you sit and 
think about how it works for him and:  “ This should 
have been checked, and is it really necessary to take 
this [drug]? ” Now I hardly reﬂ ect on it, and that ’ s 
a little scary. (Nurse) 
 However, both the pharmacists and the GPs experi-
enced a greater inﬂ uence on drug dispensing, and 
they both argued for improved quality in the han-
dling of drugs after the implementation of MDD. 
This happened despite the fact that the doctors 
admitted that not all GPs work at the same level of 
accuracy with regard to medication records, in effect 
saying that not all GPs ’ medication records were to 
be trusted: 
 … doctors have varying levels of accuracy, then. 
Some are very accurate and some are not. It is much 
more comfortable to be a stand-in for the doctors who 
are relatively accurate than for the others. (GP) 
 The medical secretaries also conﬁ rmed this: 
 Yes, there have been changes [in drug prescrip-
tions] and in and out of hospital, they [GPs] need 
to update them [the medical records] then. They 
have not always been so good at it previously. 
(Medical secretary) 
 The GPs believed that electronic communication 
could improve the exchange of information and 
updating, and thus produce an even better effect 
from the MDD system. 
 Discussion 
 This study has demonstrated that health personnel 
preserved trust in the MDD system even if the sys-
tem caused new errors and changes to the routines 
and roles of the health personnel involved. The 
impact of healthcare professionals ’ attitudes towards 
the new system and views concerning their own and 
others ’ roles are likely to affect the implementation 
process and outcome. 
 Limitations of the study 
 Focus-group interviews were conducted to get a bet-
ter understanding of the attitudes and experiences 
among involved health personnel in relation to imple-
mentation of MDD in the home-care services [11]. 
The results stem from a single implementation and 
any generalization of the ﬁ ndings should be made 
cautiously. Successful implementation of a new tech-
nology in one organization might well become a 
failure in another [12]. 
 The ﬁ rst author was observing the interviews. 
She was also a member of the project group respon-
sible for the implementation of MDD and has been 
a community pharmacist engaged in researching 
methods to reduce the number of medical errors in 
primary care. This might have inﬂ uenced how the 
participants expressed their attitudes towards the 
MDD system and the implementation process, as 
well as the role of pharmacists. Observer triangula-
tion was used to diminish this risk of bias. 
 The timing of the interviews in relation to the 
implementation process also has to be considered. In 
an early phase of implementation, engagement and 
an optimistic attitude may inﬂ uence the way the 
people involved describe a new system [13]. How-
ever, later on they might have adapted to problems 
by way of  “ work-arounds ” [14]. 
 New technology and the signiﬁ cance of trust 
 The issue of trust stands out as important in respect 
of any system implementation [15]. The details 
surrounding the MDD system are mostly invisible 
to the health personnel, and the work put into it is 
to some extent also separated in both time and 
space from the end-users. Hence it may be under-
stood and analysed as an abstract (expert) system 
[16]. In addition, the implementation of systems 
and concurrent reorganization of work raise the 
issue of trust in colleagues. This makes it important 
to understand the relationship and interplay 
between system trust and personal trust to be able 
to understand the intra-organizational implemen-
tation process [17]. 
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 We would argue that trust in the MDD system 
and the new professional roles were established 
through the implementation process. The imple-
mentation project succeeded in involving the 
affected health personnel in the planning of the new 
system. It established responsibility as well as new 
uniform collaboration routines. These are impor-
tant success factors, as underlined by others who 
have studied implementation of MDD systems 
[4,18]. However, we have not been able to ﬁ nd any 
other studies explicitly discussing trust as an issue 
in drug dispensing. 
 The informants indicated a common expectation 
for the MDD system to reduce the discrepancies 
between medication records at the GPs ’ practices 
and in the home-care services. In a parallel study 
undertaken by the authors, their expectations were 
largely conﬁ rmed [19]. Even so, health personnel 
remained conﬁ dent in the new system even when 
coming across new types of errors caused by the 
introduction of MDD. Unfortunately, the introduc-
tion of new errors is quite common when new tech-
nology or changes in routines are introduced 
[20 – 23]. 
GPs indicated that they were content with the 
introduction of MDD. We know from earlier studies 
that GPs are not always conscientious in keeping up 
their medication records [24 – 26] and this was also 
reafﬁ rmed through the interviews. The GPs as well 
as the medical secretaries would not always trust the 
medication records of their GP colleagues. Some 
patients are well known to their GPs through con-
tinuous and frequent encounters over time and stud-
ies have shown that GPs are very rational both with 
regard to how and with regard to what they docu-
ment for their own sake in the EHR [27]. On the 
other hand, the GPs were pleased with the new and 
more extensive cooperation with the pharmacy intro-
duced by MDD. A recent study on the value of 
physician/pharmacist/nurse cooperation in nursing 
homes has shown impact on optimizing medication 
use [28]. 
 Nurses were anxious about losing their skills as 
good observers of patients. One could attempt to 
compensate for uncertainty in new technology either 
by keeping up old routines in parallel, or by trying to 
ﬁ nd other ways of obtaining the same information [13]. 
Additionally, the tasks that belong to their role are 
many and integrated. Planners sometimes underesti-
mate the extent to which taking away one task might 
have unintended and negative effects on others [20]. 
The nurses might be justiﬁ ed in expressing scepticism 
towards the new system [29]. On the other hand, 
some would claim that the discontent from the nurses 
is more about the protection of their own role rather 
than scepticism towards the MDD system. 
 Future research 
 The nursing role has previously been described as the 
last defence in a safety net to prevent errors [30]. Our 
group of nurses reported that less attention was paid 
to medications after the introduction of MDD. Instead 
the pharmacy was highlighted as a new safety net. 
More research is needed to look into the consequences 
of this potential change in responsibility. The signiﬁ -
cance of new types of errors following the intro-
duction of MDD also needs further investigation. 
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Background
With multidose drug dispensing (MDD), patients 
receive their drugs in machine-dispensed dose units, 
packed in disposable bags. The dose unit bags are 
labelled with patient data, drug content data, and 
time for intake [1−3]. For patients receiving multi-
dose-dispensed drugs, all prescriptions issued by the 
patients’ GPs are ordered through a local pharmacy, 
which electronically forwards the total orders to an 
MDD supplier. Dispensed drugs are returned to the 
pharmacy, and home care services deliver the dose 
units to the patients [4]. For patients using home 
care services, each supply of drugs usually covers 2 
weeks of use. In 2011 there were about 53,000 users 
of multidose-dispensed drugs in Norway. Three out 
of four of these users were patients using home care 
services [5].
Residents in Norway are entitled to a regular GP 
[6]. Formally, these GPs are required to keep updated 
medication records for all their patients, including 
changes that derive from visits to hospitals or other 
physicians. Home care services offer assistance with 
medication for patients living at home; this makes 
GPs’ prescription routines and cooperation with other healthcare 
personnel before and after implementation of multidose drug 
dispensing
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Background: This study addresses GPs’ attitudes towards multidose drug dispensing before and after implementation and 
their perceived experience of how multidose drug dispensing affects prescription and communication routines for patients 
in the home care services. This study contributes to a method triangulation with two other studies on the introduction 
of multidose drug dispensing in Trondheim. Methods: A controlled before-and-after study carried out in Trondheim 
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the nurses in the home care services responsible for 
the administration and observation of patients’ drug 
use. However, GPs and home care services are sepa-
rate organisations in primary care in Norway. They 
are usually not located together and they keep sepa-
rate medication records. To avoid adverse drug 
events, home care services rely on close collaboration 
with GPs and pharmacies [7−9]. The need for coop-
eration between different groups of health personnel 
and coordination of tasks related to medications is 
even stronger under the MDD system [1,10−12].
Medication errors are any errors in the process of 
prescribing, transcribing, dispensing, or administer-
ing a drug [13]. Research shows that errors resulting 
in preventable adverse drug events most often occur 
at the stage of ordering [14]. The prescribing of 
drugs includes prescribing decisions and prescription 
writing, and errors occur in both parts of this process 
[15]. In this study, we focused on the prescription 
writing part of the process.
Aims
The aims of this study were to investigate (1) GPs’ 
attitudes and experiences gained in relation to the 
introduction of MDD, and (2) GPs’ prescribing, 
communication, and collaborative work routines 
before and after the implementation of the system. 
This study contributes to a method triangulation, i.e. 
checking the validity of the findings from two other 
studies by cross-checking them with another.
Materials and methods
The introduction of MDD in Trondheim (interven-
tion) was organised by the municipal healthcare 
management and gradually adopted in 2006. Unlike 
most other municipalities in Norway using MDD, 
Trondheim decided to use the GPs’ medication 
record in the electronic health record (EHR) as the 
master medication record. Hence, other health per-
sonnel had to manually update the medication record 
in their own EHR in accordance with the GPs’. 
According to the local routines, only the patients’ 
regular GP was allowed to prescribe drugs for inclu-
sion in the patient’s multidose drug packages.
In order to assess the influence of MDD on medica-
tion practices from a professional perspective, a ques-
tionnaire survey for comparison was carried out. The 
city of Tromsø was strategically selected as a control. 
Tromsø (67,000 inhabitants) and Trondheim (170,000 
inhabitants) are two medium-size towns in Norway. 
They both have a large university hospital and are the 
administration centres in their respective regions. Both 
towns have been in the forefront of introducing infor-
mation and communication technology in primary 
care. However, the one important difference was that 
Tromsø had not planned to implement MDD.
When MDD was implemented in the home care 
services, Trondheim was organised in 27 home care 
units, compared to eight units in Tromsø. In total, 
about 1800 patients received assistance with the han-
dling of drugs in Trondheim and approximately 800 
patients in Tromsø. Five out of 17 pharmacies in 
Trondheim were involved as multidose drug provid-
ers. Tromsø had six pharmacies.
Questionnaires
A questionnaire was distributed to all GPs in 
Trondheim and Tromsø in 2005/2006 and in 2008. 
In Trondheim the total number of GPs was 123 
(2005/2006) and 137 (2008), while in Tromsø the 
number of GPs was 52 in both years. The question-
naires had questions about prescription routines and 
communication and cooperation with home care ser-
vices and pharmacies regarding medication (Table I).
The questionnaires had a multiple-choice design 
including optional free-text comments. The ques-
tionnaires were identical for both towns; however, 
only GPs in Trondheim (the intervention group) 
were questioned about experiences and expectations 
of MDD. In 2008, the GPs in Trondheim were 
asked separate questions in relation to their routines 
for follow up of patients with MDD and with ordi-
nary prescriptions (OP).
Table I. Themes in the questionnaires and example questions.
Theme Example question Response categories
Responsibility Does the EHR clearly indicate that the home care services 
handle the medication for the patient?
Always, mostly, sometimes, never
Prescription management Are the drug requisitions from home care services cross-
checked against the medication record in the EHR?
Routinely, only when in doubt
Communication Does the patient get a copy of the medication record in the 
EHR when changes have been made during the consultation?
Always, mostly, sometimes, never
Expected/experienced changes Overview of the patient’s drug use More, unchanged, less
EHR, electronic health record.
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In Trondheim, the first questionnaire was distrib-
uted at a professional meeting, while the second one 
was sent and collected by mail. In Tromsø, both 
questionnaires were handed out and collected at the 
GPs’ offices. One reminder was given after 3 weeks. 
All the responses were kept anonymous.
Statistical analysis
Descriptive and statistical analyses were completed 
using SPSS. Mean values and absolute and relative 
frequencies (%) are presented. A two-sample t-test 
was used to compare mean values of characteristics 
between the GPs in Trondheim and Tromsø. Fisher’s 
Exact test was used to compare the distribution of 
categorical factors (proportions) between the years of 
assessment (2005 vs. 2008) and between towns 
(Trondheim and Tromsø). An ordinary logistic 
regression analyses was used to examine whether the 
difference in odds of changing routines (e.g. updat-
ing of medication records) from 2005 to 2008 dif-
fered for Trondheim (intervention area) and Tromsø 
(control area), technically represented by an interac-
tion term in the statistical model. Separate analyses 
were performed for responses that related to MDD 
patients and patients with OP, respectively (defined 
for Trondheim only). p-values <0.05 were consid-
ered statistically significant.
Approval
The study was approved by the Regional Committee 
for Medical Research Ethics (REK) and the 
Norwegian Social Science Data Services (NSD).
Results
The response rates and characteristics from the GPs 
are listed in Table II. The only significant difference 
between Trondheim and Tromsø is the number of 
patients per GP in 2005. Out of 1800 patients in the 
home care services, 1500 were enrolled in the MDD 
system by the end of the study. This gave a mean of 
11 multidose drug patients per GP.
Expectations and experiences
Table III shows a great concurrence between the 
GPs’ expectations before and experiences after the 
implementation of MDD. There was only one sig-
nificant difference before and after. Many GPs expe-
rienced the workload after the implementation of 
MDD to be heavier than expected.
Most GPs both expected and experienced MDD 
to give a better overview of the patients’ medication 
and contribute to a reduction in medication errors. 
Cooperation with both home care services and 
pharmacies improved, and this was also expected 
beforehand.
Use of the electronic health record
Table IV presents information about how the GPs 
use the EHR when prescribing drugs to patients in 
home care services. Both in 2005 and in 2008, the 
GPs in Trondheim updated medication records in 
the EHR to a greater extent than their colleagues in 
Tromsø. The change in updating routines was not 
significant in either of the two towns, and neither was 
the difference in change showed by the interaction 
p-value.
In the second round, we also asked if the GPs in 
Trondheim recorded the information that the patient 
was a MDD user. The latter question indirectly gave 
the information that the patient got assistance with 
medication from home care services, since only 
patients in home care services used MDD at the 
time. In Tromsø, we found a significant increase over 
the study period of GPs who “always” or “usually” 
recorded in the EHR which patients received 
Table II. Response rates and characteristics of the GPs in Tromsø and Trondheim in 2005 and 2008.
Before intervention (2005) After intervention (2008)
 Trondheim Tromsø p-value Trondheim Tromsø p-value
Response 82 (67) 39 (75) 0.37a 91 (66) 29 (56) 0.18a
Age (years) 46±10 44±10 0.35b 48±11 48±12 0.82b
Patients 1447±283 1273±289 0.003b 1385±327 1280±254 0.08b
Years in general practice 15±10 13±10 0.34b 16±11 17±11 0.65b
Specialists in general practice 50 (61) 27 (69) 0.50a 58 (64) 22 (76) 0.26a
Gender
 Women Not asked Not asked − 24 (26) 12 (41) 0.13a
 Men − 67 (74) 17 (59)  
Values are n (%) or mean±SD. aFisher’s Exact test for difference in proportions. bTwo-sample t-test for difference in mean values.
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assistance. This was not the case in Trondheim for 
patients with OP, only for MDD users (Table IV).
More GPs in Trondheim reported that they con-
sulted the EHR when prescribing to home care 
patients in 2008 than in 2005. The increase was sig-
nificant only for MDD patients. In Tromsø the per-
centage consulting their EHR was higher at start 
than in Trondheim, but the percentage stayed the 
same. This made the change in routine in Trondheim 
significant compared to Tromsø.
The routines providing patients with a medication 
record printout changed in both towns, giving no sig-
nificant change in the intervention group compared 
with the control group.
Other findings
The majority of GPs in Trondheim (81%) always or 
usually contacted the pharmacy when medication 
changes were made for multidose drug users. 
However, only 28% of the GPs did the same for 
patients with OP. The GPs in Tromsø did not com-
municate medication changes directly to the phar-
macy in 2005 or in 2008.
Concerning which physicians should be allowed to 
prescribe multidose-dispensed drugs, 53% of the GPs in 
Trondheim indicated that only GPs should be allowed 
to do so. The other half would accept MDD prescrip-
tions from physicians in hospitals, nursing homes, pri-
vate specialists, or a combination of the above.
The majority of the GPs in Trondheim (69%) 
wanted MDD to be continued, while 7% (all men) 
did not, and 24% were uncertain. No differences 
were seen with regards to the age of the GPs, the 
number of patients on their lists, or whether the GPs 
were specialists in general practice.
Discussion
GPs in Trondheim reported an improved overview of 
their patients’ medications and increased collabora-
tion with other healthcare personnel after the imple-
mentation of MDD. Improved prescription routines 
were reported in both the intervention and the con-
trol group. The changes in prescribing routines 
reported for MDD users did not always apply to 
patients using home care services with OP. Despite 
the increased workload, most of the GPs wanted 
MDD to be continued.
Triangulation
This study contributes to a method triangulation. 
Table V shows what findings in this study are 
Table III. Reported effects of multidose drug dispensing among GPs in Trondheim.
Before intervention (2005) After intervention (2008) p-value
Overview of the patients’ medications
 More 65 (82) 71 (80) 0.64a
 No change 14 (18) 17 (19)  
 Less 0 (0) 1 (1)  
Medication errors
 More 6 (8) 4 (5) 0.14
 No change 13 (17) 26 (30)  
 Less 56 (75) 56 (65)  
Cooperation with homecare services
 More 42 (56) 46 (52) 0.76
 No change 29 (39) 36 (40)  
 Less 4 (5) 7 (8)  
Cooperation with the pharmacy
 More Not asked 69 (78) −
 No change 20 (22)  
 Less 0 (0)  
Workload for the GP
 More 41 (55) 75 (83) 0.001a
 No change 30 (40) 14 (16)  
 Less 4 (5) 1 (1)  
Workload for the medical secretary
 More 23 (31) 38 (43) 0.21
 No change 42 (57) 38 (43)  
 Less 9 (12) 12 (14)  
Values are n (%). Fisher’s Exact test for difference in proportions. aTwo last categories combined to avoid frequency below five in the cross 
tabulation.
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supported by findings in the two previously published 
studies [16,17]. The use of both qualitative and quan-
titative methods is advocated to help explain findings. 
This approach may be particularly appropriate for the 
evaluation of patient safety interventions [18].
The GPs reported an improved overview of the 
patients’ drugs. This finding corresponds to findings 
in the parallel quantitative study of medication 
records showing a reduction in discrepancies between 
medication records at the GP’s office and in the 
home care services when MDD was introduced [17]. 
This may be explained by MDD’s capability of 
encouraging enhancement of communication 
between other healthcare personnel and GPs about 
prescriptions. The improved flow of information 
from home care nurses and pharmacists to GPs was 
confirmed in the qualitative study about trust 
between the collaborating partners [16].
The GPs in Trondheim were better at updating 
medication records in the EHR than their colleagues 
in Tromsø even before the implementation of MDD. 
The high initial level of updating could explain why 
the reported improvement in the updating of medi-
cation records in this study did not become statisti-
cally significant. Still, the study of discrepancies in 
medication records in Trondheim showed a reduc-
tion in discrepancies during implementation [17]. In 
2003, a study from Trondheim was published that 
showed a great number of discrepancies between the 
medication records held by GPs and home care ser-
vices for the same patients [19]. The study drew a lot 
of attention to medication errors in Trondheim just 
prior to our study and may have contributed to our 
results. Given all this earlier attention, one may 
assume the possible room for improvement was 
somewhat reduced.
Table IV. Reported routines related to the use of electronic health record (EHR) before and after implementation of multidose drug 
dispensing.
n (%) OR (95% CI) Interaction p-value, Trondheim vs. Tromsø
Updating the medication record in EHR 0.81
 Trondheim
  2005 36 (43.9) 1.00a  
  2008 50 (61.7) 1.64 (0.90−3.00)  
 Tromsø
  2005 6 (15.4) 1.00a  
  2008 6 (20.7) 1.44 (0.59−3.47)  
Recording in EHR that the home care services handle the patient’s medication OP: 0.032; MDD: 0.051
 Trondheim
  2005 29 (35.8) 1.00b  
  2008 OP 39 (45.3) 1.49 (0.80−2.77)  
  2008 MDD 79 (88.7) 14.17 (6.37−31.51)  
 Tromsø
  2005 20 (51.3) 1.00b  
  2008 24 (82.9) 4.56 (2.02−10.28)  
Consulting the EHR when prescribing to patients in home care services OP: 0.54; MDD: 0.005
 Trondheim
  2005 44 (53.7) 1.00c  
  2008 OP 57 (64.0) 1.54 (0.83−2.84)  
  2008 MDD 78 (85.7) 5.18 (2.50−10.75)  
 Tromsø
  2005 28 (73.7) 1.00c  
  2008 22 (75.9) 1.12 (0.51−2.47)  
Providing printouts of medication records in the EHR when changes are made during 
consultation
OP: 0.071; MDD: 0.10
 Trondheim
  2005 26 (31.7) 1.00b  
  2008 OP 44 (48.4) 2.02 (1.08−3.75)  
  2008 MDD 45 (50.6) 2.20 (1.18−4.11)  
 Tromsø
  2005 6 (15.4) 1.00b  
  2008 14 (48.3) 5.13 (2.30−11.45)  
EHR, electronic health record; MDD, multidose drug dispensing; OP, ordinary prescriptions. aOR for response category “Always”. bOR 
for response category “Always” and “Usually”. cOR for response category “Routinely”.
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The increased involvement of the GP and 
improved routines in the handling of medications for 
MDD users, according to our findings, did not nec-
essarily apply to patients in home care services with 
OP, neither in terms of consulting their EHR nor in 
collaborating with the pharmacy. For patients with 
OP, nurses in home care services can make changes 
in medications based on other physicians’ prescrip-
tions without involving and consulting the patient’s 
regular GP. This implies that the introduction of 
MDD forced the GPs to assume greater responsibil-
ity for the medication of their patients. This finding 
agrees with our qualitative study, in which both GPs 
and pharmacists experienced a greater influence and 
improved quality in the handling of drugs after the 
implementation of MDD [16]. Changes in routines 
with the use of MDD seem to support the view that 
it leads GPs to pay more attention to the complete 
medication record rather than just single prescrip-
tions [10]. On the other hand, the finding that 47% 
of the GPs reported that other physicians should be 
able to provide prescriptions to their MDD patients 
somewhat contradicts this.
Strengths and limitations
This study has examined an intervention at the 
organisational level, which meets the criteria desig-
nating a complex intervention [20]. The methods 
and statistics commonly preferred in connection with 
interventions are difficult to apply to complex inter-
ventions in large organisations. It is also recom-
mended that one should be flexible and adapt the 
protocol to local conditions [20]. The results pre-
sented stem from a single implementation and should 
thus only be generalised with great caution. The 
strength of the study lies in the use of method 
triangulation.
Some of the results presented lack statistical sig-
nificance. An increased number of informants could 
have changed that. The control group could have 
been made larger by including other towns, but it 
would also introduce greater variety and potentially 
more confounders [20]. In a controlled before-and-
after design, one should require a minimum detect-
able effect size of 30% [21]. This is not seen in any of 
the non-significant results. Increasing the number of 
doctors would thus probably not add new informa-
tion. Recruitment of large comparable organisations 
is very difficult, and was, moreover, beyond the 
resources and capabilities of the project.
The questionnaires were distributed differently in 
Trondheim in 2005 and in 2008, as described in the 
method section. Nevertheless, the response rates 
were high on both occasions and there are no indica-
tions that this change affected the answers. The 
wording of the questions is crucial when it comes to 
valid answers, and we cannot exclude the possibility 
that some responders may have misinterpreted single 
questions. Minor changes in layout and wording in 
the questionnaires may have contributed to this.
As the questionnaires were answered anony-
mously, it was not possible to directly link the answers 
from 2005 with those from 2008. The statistical test-
ing is performed with tests on independent samples, 
even though the GPs were mainly the same.
Table V. Findings in the different studies contributing to the triangulation method.
Findings Study I (controlled before−after 
study of discrepancies in 
medication records)17
Study II (qualitative study 
based on focus group 
interviews)16
This study (controlled 
before−after questionnaire 
study among GPs)
Improved updating of medication records by 
the GPs during implementation of MDD
Yes Yes No
Increased overview of the patients’ 
medications
Yes Yes Yes
Increased cooperation between the GPs and 
the pharmacy concerning the medicating of 
MDD patients
Yes Yes Yes
Improved communication between health 
personnel regarding prescriptions in the 
MDD system
− Yes Yes
GPs assumed greater responsibility for the 
medications of their patients when enrolled 
in the MDD system
− Yes Yes
The GPs trusted the MDD system − Yes Yes
The GPs wanted the MDD system to remain 
in use
− Yes Yes
Increased workload for the GPs − Yes Yes
−, Not asked.
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To our knowledge, no systematic intervention in 
drug prescribing took place in Tromsø during the 
study. Still, we observed that some routines seemed 
to have changed more in Tromsø than in Trondheim 
(Table IV). Actually, some of the GPs’ routines in 
Tromsø and Trondheim became more similar over 
the course of the study. This was the case for the 
routine for handing out printouts of the medication 
record to the patients (Table IV). Hence, it is possi-
ble that other external causes or confounders might 
have overshadowed some effects of the introduction 
of MDD. This could have been partly avoided by 
running the after study closer in time to the imple-
mentation, but that would have placed the findings 
in danger of being influenced by start-up problems. 
The GPs’ change of routines may also be attributed 
to the Hawthorne effect in both places. This is also 
one of the reasons why it is important to establish a 
control group when the results of an intervention are 
assessed [22].
Regulation of the prescription of multidose-
dispensed drugs
In Trondheim, the authorities decided to restrict the 
power to prescribe drugs for inclusion in the multi-
dose bags to the patients’ regular GP. This was in 
contrast to what has been done in other sites in 
Norway where MDD has been implemented. After 
having tried MDD, only half of the GPs were in 
favour of restricting multidose drug prescribing to 
GPs. A Swedish study has similarly shown a great 
variation among GPs in their opinion of who should 
be responsible for patients’ drug lists [23].
However, having more than one physician involved 
in the patients’ care is associated with higher risks of 
medication errors [24,25]. This has also been the 
case using multidose-dispensed drugs [26]. Similarly, 
in a recently published Norwegian questionnaire 
study with 54 GPs, a majority of the GPs reported an 
improved overview of patients’ drugs in the MDD 
system, but comments from some of the physicians 
indicated that MDD works best when the patient’s 
regular GP alone is responsible for the medications 
[27]. This feedback seems to support the local regu-
lation made in Trondheim restricting the prescrip-
tion of multidose-dispensed drug to the patient’s GP.
The GPs wanted MDD to be continued
It is interesting to note that a majority of the GPs 
wanted MDD to be continued, even though the GPs 
experienced an increased workload after the imple-
mentation of MDD, which exceeded the GPs’ prior 
expectations. A Finnish study concluded that policies 
that reduced job demands and increased job control 
would probably lead to an increased organisational 
commitment among GPs [28]. In our questionnaire, 
the GPs reported increased control, as they experi-
enced a better overview, a supposed reduction in 
medication errors, and improved cooperation with 
other health personnel.
The implementation process
The positive attitude GPs in Trondheim reported 
towards MDD has not been reported in other studies 
[12,29]. One reason may be that Trondheim was 
able to involve GPs to a greater extent than in other 
places where MDD has been introduced. The impor-
tance of information work and involvement when 
implementing new technologies, are highlighted in 
the literature [30]. It is important to create expecta-
tions and responsibility towards the routine changes 
demanded by the new technology.
We would argue that the pharmacy became an 
important communication partner within the MDD 
system. This has also been reported by others [10]. 
In another study, GPs reported uncertainty over 
whether the pharmacy or the home care services 
should be notified of new prescriptions and changes 
in medications, because the different home care units 
had different routines [29]. Using a system in a col-
laborative setting requires a systematic approach by 
and towards all participants involved. The establish-
ment of common and well-known routines seems to 
be an important factor in successful MDD imple-
mentation, and direct communication should be 
encouraged.
Conclusion
GPs in Trondheim welcomed MDD despite the 
increased workload. Implementation of the system 
improved prescription practices and communication 
and collaboration between the different healthcare 
personnel involved. Restricting the right to prescribe 
multidose-dispensed drugs to the GPs probably made 
the GPs take a greater responsibility for the patients’ 
medications. The divergence in attitude towards 
MDD among GPs in different studies needs more 
attention, and further research may also be needed to 
refine the process of implementation of MDD.
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